Propanc Biopharma (PPCB) 10-Q 14 Feb 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Dec. 31, 2019	Feb. 13, 2020
Cover [Abstract]
Entity Registrant Name	Propanc Biopharma, Inc.
Entity Central Index Key	0001517681
Document Type	10-Q
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,189,370
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Jun. 30, 2019
CURRENT ASSETS:
Cash	$ 12,022	$ 2,394
GST tax receivable	2,432	5,439
Prepaid expenses and other current assets	6,334	83,299
TOTAL CURRENT ASSETS	20,788	91,132
Security deposit - related party	2,109	2,103
Operating lease right-of-use assets, net - related party	35,391
Property and equipment, net	7,137	8,417
TOTAL ASSETS	65,425	101,652
CURRENT LIABILITIES:
Accounts payable	826,853	917,337
Accrued expenses and other payables	590,246	723,042
Convertible notes and related accrued interest, net of discounts and premiums	2,934,340	1,657,377
Operating lease liability - current portion - related party	14,216
Embedded conversion option liabilities	924,744	698,264
Due to former director - related parties	31,257	31,164
Loans from directors and officer - related parties	52,022	51,867
Employee benefit liability	340,637	323,837
TOTAL CURRENT LIABILITIES	5,714,315	4,402,888
NON-CURRENT LIABILITIES:
Operating lease liability - long-term portion - related party	23,094
TOTAL NON-CURRENT LIABILITIES	23,094
TOTAL LIABILITIES	5,737,409	4,402,888
Commitments and Contingencies (See Note 7)
STOCKHOLDERS' DEFICIT:
Common stock, $0.001 par value; 1,00,000,000 shares authorized; 2,234,901 and 968,042 shares issued; 2,234,852 and 967,993 outstanding as of December 31, 2019 and June 30, 2019, respectively	2,235	968
Additional paid-in capital	47,766,162	45,713,322
Accumulated other comprehensive income (loss)	1,001,191	1,066,998
Accumulated deficit	(54,400,096)	(51,041,047)
Treasury stock (49 shares)	(46,477)	(46,477)
TOTAL STOCKHOLDERS' DEFICIT	(5,671,985)	(4,301,236)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	65,425	101,652
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, 1,500,005 shares authorized, $0.01 par value:	5,000	5,000
TOTAL STOCKHOLDERS' DEFICIT	5,000	5,000
Series B Preferred Stock [Member]
STOCKHOLDERS' DEFICIT:
Preferred stock, 1,500,005 shares authorized, $0.01 par value:
TOTAL STOCKHOLDERS' DEFICIT

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Jun. 30, 2019
Preferred stock, shares authorized	1,500,005	1,500,005
Preferred stock, par value	$ 0.01	$ 0.01
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	2,234,901	968,042
Common stock, shares outstanding	2,234,852	967,993
Treasury stock, shares	49	49
Series A Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	500,000	500,000
Preferred stock, shares outstanding	500,000	500,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5	5
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
REVENUE
Revenue
OPERATING EXPENSES
Administration expenses	1,375,971	656,594	2,209,385	1,041,194
Occupancy expenses	7,592	6,449	18,224	14,527
Research and development	37	94,777	65,409	150,970
TOTAL OPERATING EXPENSES	1,383,600	757,820	2,293,018	1,206,691
LOSS FROM OPERATIONS	(1,383,600)	(757,820)	(2,293,018)	(1,206,691)
OTHER INCOME (EXPENSE)
Interest expense	(446,082)	(494,989)	(1,121,307)	(1,119,527)
Interest income	3	23	6	27
Change in fair value of derivative liabilities	(675,024)	39,470	(156,068)	(1,931,646)
Gain (loss) on debt settlements, net		(132)		14,289
Gain (loss) on extinguishment of debt, net	20,176	(20,355)	20,176	1,165,516
Foreign currency transaction gain (loss)	617,561	(333,205)	82,411	(613,912)
TOTAL OTHER INCOME (EXPENSE)	(483,366)	(809,188)	(1,174,782)	(2,485,253)
LOSS BEFORE TAXES	(1,866,966)	(1,567,008)	(3,467,800)	(3,691,944)
TAX (EXPENSE) BENEFIT	(143)	116,970	108,751	116,970
NET LOSS	$ (1,867,109)	$ (1,450,038)	$ (3,359,049)	$ (3,574,974)
BASIC AND DILUTED NET LOSS PER SHARE	$ (1.25)	$ (41.33)	$ (2.64)	$ (11.57)
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING	1,492,757	35,081	1,273,029	309,114
NET LOSS	$ (1,867,109)	$ (1,450,038)	$ (3,359,049)	$ (3,574,974)
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)	(629,494)	358,279	(65,807)	634,495
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	(629,494)	358,279	(65,807)	634,495
TOTAL COMPREHENSIVE INCOME (LOSS)	$ (2,496,603)	$ (1,091,759)	$ (3,424,856)	$ (2,940,479)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders Deficit (Unaudited) - USD ($)	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
Balance at Jun. 30, 2018	$ 5,000		$ 93	$ 38,214,213	$ (45,282,678)	$ (46,477)	$ 357,929	$ (6,751,920)
Balance, shares at Jun. 30, 2018	500,000	1	92,859
Issuance of common stock for conversion of convertible debt and accrued interest			$ 258	1,413,060				1,413,318
Issuance of common stock for conversion of convertible debt and accrued interest, shares			258,285
Reclassification of premium upon debt conversion				600,209				600,209
Extinguishment of derivative liability associated with convertible notes				1,029,039				1,029,039
Exercise of warrants				30				30
Exercise of warrants, shares			24
Foreign currency translation gain (loss)							276,216	276,216
Net loss					(2,124,936)			(2,124,936)
Balance at Sep. 30, 2018	$ 5,000		$ 351	41,256,551	(47,407,614)	(46,477)	634,145	(5,558,044)
Balance, shares at Sep. 30, 2018	500,000	1	351,168
Balance at Jun. 30, 2018	$ 5,000		$ 93	38,214,213	(45,282,678)	(46,477)	357,929	(6,751,920)
Balance, shares at Jun. 30, 2018	500,000	1	92,859
Foreign currency translation gain (loss)								(613,912)
Net loss								(3,574,974)
Balance at Dec. 31, 2018	$ 5,000		$ 547	44,002,122	(48,857,652)	(46,477)	992,424	(3,904,036)
Balance, shares at Dec. 31, 2018	500,000	1	546,555
Balance at Sep. 30, 2018	$ 5,000		$ 351	41,256,551	(47,407,614)	(46,477)	634,145	(5,558,044)
Balance, shares at Sep. 30, 2018	500,000	1	351,168
Issuance of common stock for conversion of convertible debt and accrued interest			$ 128	1,094,972				1,095,100
Issuance of common stock for conversion of convertible debt and accrued interest, shares			127,685
Issuance of common stock under put premium			$ 54	574,506				574,560
Issuance of common stock under put premium, shares			54,000
Reclassification of premium upon debt conversion				708,184				708,184
Issuance of common stock for offering costs			$ 8	298,915				298,923
Issuance of common stock for offering costs, shares			7,702
Foreign currency translation gain (loss)							358,279	358,279
Issuance of common stock for services			$ 6	68,994				69,000
Issuance of common stock for services, shares			6,000
Net loss					(1,450,038)			(1,450,038)
Balance at Dec. 31, 2018	$ 5,000		$ 547	44,002,122	(48,857,652)	(46,477)	992,424	(3,904,036)
Balance, shares at Dec. 31, 2018	500,000	1	546,555
Balance at Jun. 30, 2019	$ 5,000		$ 968	45,713,322	(51,041,047)	(46,477)	1,066,998	(4,301,236)
Balance, shares at Jun. 30, 2019	500,000	1	968,042
Issuance of common stock for conversion of convertible debt and accrued interest			$ 182	123,531				123,713
Issuance of common stock for conversion of convertible debt and accrued interest, shares			181,939
Reclassification of premium upon debt conversion				73,235				73,235
Foreign currency translation gain (loss)							563,687	563,687
Relative fair value of warrants issued with convertible debt				375,905				375,905
Issuance of common stock for services			$ 20	39,780				39,800
Issuance of common stock for services, shares			20,000
Stock based compensation in connection with stock option grants and restricted stock unit grants				75,104				75,104
Net loss					(1,491,940)			(1,491,940)
Balance at Sep. 30, 2019	$ 5,000		$ 1,170	46,400,877	(52,532,987)	(46,477)	1,630,685	(4,541,732)
Balance, shares at Sep. 30, 2019	500,000	1	1,169,981
Balance at Jun. 30, 2019	$ 5,000		$ 968	45,713,322	(51,041,047)	(46,477)	1,066,998	(4,301,236)
Balance, shares at Jun. 30, 2019	500,000	1	968,042
Foreign currency translation gain (loss)								82,411
Net loss								(3,359,049)
Balance at Dec. 31, 2019	$ 5,000		$ 2,235	47,766,162	(54,400,096)	(46,477)	1,001,191	(5,671,985)
Balance, shares at Dec. 31, 2019	500,000	1	2,234,901
Balance at Sep. 30, 2019	$ 5,000		$ 1,170	46,400,877	(52,532,987)	(46,477)	1,630,685	(4,541,732)
Balance, shares at Sep. 30, 2019	500,000	1	1,169,981
Issuance of common stock for conversion of convertible debt and accrued interest			$ 1,065	218,401				219,466
Issuance of common stock for conversion of convertible debt and accrued interest, shares			1,064,920
Reclassification of premium upon debt conversion				86,970				86,970
Foreign currency translation gain (loss)							(629,494)	(629,494)
Stock based compensation in connection with stock option grants and restricted stock unit grants				75,104				75,104
Stock based compensation in connection with fair value of warrants issued for services				984,810				984,810
Net loss					(1,867,109)			(1,867,109)
Balance at Dec. 31, 2019	$ 5,000		$ 2,235	$ 47,766,162	$ (54,400,096)	$ (46,477)	$ 1,001,191	$ (5,671,985)
Balance, shares at Dec. 31, 2019	500,000	1	2,234,901

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,359,049)	$ (3,574,974)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Issuance and amortization of common stock and warrants for services	1,024,610	69,000
(Gain) loss on settlements, net		(14,289)
Foreign currency transaction loss (gain)	(82,411)	613,912
Depreciation expense	1,270	1,068
Amortization of debt discounts	307,085	303,813
Change in fair value of derivative liabilities	156,068	1,931,646
Gain on extinguishment of debt	(20,176)	(1,165,516)
Stock option and restricted stock expense	150,208
Accretion of put premium	698,307	699,230
Changes in Assets and Liabilities:
GST receivable	3,024	(2,757)
Prepaid expenses and other assets	76,990	(53,104)
Accounts payable	(93,233)	(26,388)
Deferred rent	1,921
Employee benefit liability	15,829	177,232
Accrued expenses	(134,768)	(51,533)
Accrued interest	111,448	107,643
NET CASH USED IN OPERATING ACTIVITIES	(1,142,877)	(1,056,786)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory notes, net of original issue discounts and issue costs	1,130,000	1,054,089
Repayments of convertible promissory notes		(219,000)
Proceeds from the issuance of common stock		405,773
Fees associated with offering costs		(15,000)
Proceeds from the exercise of warrants		30
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,130,000	1,225,892
Effect of exchange rate changes on cash	22,505	(62,827)
NET INCREASE IN CASH	9,628	104,617
CASH AT BEGINNING OF PERIOD	2,394	19,921
CASH AT END OF PERIOD	12,022	124,538
Supplemental Disclosure of Cash Flow Information
Interest	4,467	8,585
Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Reduction of put premium related to conversions of convertible notes	160,205	1,308,393
Conversion of convertible notes and accrued interest to common stock	318,768	2,508,421
Proceeds receivable from the issuance of common stock		168,787
Discounts related to warrants issued with convertible notes	375,904
Deferred financing costs associated with equity purchase agreement		298,923
Discounts related to derivative liability	115,000	50,000
Settlement of accounts payable for shares of common stock
Issue and amortization of common stock and warrants for services	1,024,610	69,000
Operating lease right-of-use asset and operating lease liability recorded on adoption of ASC 842	$ 46,696

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting and Reporting Policies	6 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Nature of Operations and Summary of Significant Accounting and Reporting Policies	NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated in Melbourne, Victoria Australia on October 15, 2007 as Propanc PTY LTD, and continues to be based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. On November 23, 2010, the Company was incorporated in the state of Delaware as Propanc Health Group Corporation. In January 2011, to reorganize the Company, we acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of December 31, 2019, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to better reflect the Company’s stage of operations and development. The Company has filed multiple patent applications relating to its lead product, PRP. The first application was filed in October 2010 in each of the countries listed in the table below. This application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Hong Kong, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, Republic of Korea and India. In Brazil and Canada, the patent application remains under examination. In 2016 and 2017 we filed other patent applications, as indicated below. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, which allows the applicants to seek protection for an invention in over 150 countries. Once national or regional applications are filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national or regional phase. One PCT application, filed in November 2016, entered the national phase in July 2018 in each of the countries listed in the table below. A second application filed in January 2017 entered the national phase commencing July 2018. A third application entered the national phase in October 2018. No. Title Country Case Status Date Filed 1. A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic reduction agent. USA, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Hong Kong, Japan, Indonesia, Israel, New Zealand, Malaysia, Singapore, Malaysia South Africa, Mexico, Republic of Korea and India Granted Oct-22-2010 Brazil and Canada Under Examination Divisional applications filed and under examination in Mexico and China USA Divisional application granted 2. Proenzyme composition Australia, Canada, China, Europe, Hong Kong, India, Indonesia, Israel, Japan, Malaysia, New Zealand, Singapore, South Africa and USA Application filed and pending Nov-11-2016 3. Cancer Treatment Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Malaysia, New Zealand, Singapore and USA Application filed and pending Jan-27-2017 4. Composition of proenzymes for cancer treatment Australia, China, Europe, Japan and USA Application filed and pending Apr-12-2017 The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. Decrease in Authorized Common Stock and Reverse Split On June 24, 2019, the Company effected a one-for-five hundred (1:500) reverse stock split whereby the Company (i) decreased the number of authorized shares of common stock, $0.001 par value per share, to 100,000,000 and (ii) decreased by a ratio of one-for-five hundred (1:500) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the consolidated financial statements to reflect the reverse stock split. On February 4, 2020 the Directors resolved to increase the Common Stock of the Company from 100,000,000 authorized shares to 1,000,000,000 authorized shares and believes that such number of authorized shares of Common Stock will be in the best interests of the Corporation and its stockholders because the Board believes that the availability of more shares of Common Stock for issuance will allow the Corporation greater flexibility in pursuing financing from investors, meeting business needs as they arise, taking advantage of favorable opportunities and responding to a changing corporate environment. The Company filed the necessary documents with the U.S. Securities and Exchange Commission on February 6, 2020 and at the date of this filing the increase in authorized shares to 1,000,000,000 has not yet been effected. Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three and six months ended December 31, 2019 and 2018 and cash flows for the six months ended December 31, 2019 and 2018 and our financial position at December 31, 2019 have been made. The Company’s results of operations for the three and six months ended December 31, 2019 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2020. Reference is frequently made herein to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”). This is the source of authoritative US GAAP recognized by the FASB to be applied to non-governmental entities. Each ASC reference in this Quarterly Report is presented with a three-digit number, which represents its Topic. As necessary for explanation and as applicable, an ASC topic may be followed with a two-digit subtopic, a two-digit section or a two-or-three-digit paragraph. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2019. The June 30, 2019 balance sheet is derived from those statements. Principles of Consolidation The condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive subsidiary at December 31, 2019. Use of Estimates The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying unaudited condensed consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar ($) and/or (USD) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. For the six months ended December 31, 2019, the Company recognized an exchange loss of approximately $575,700 on intercompany loans made by the parent to the subsidiary which have not been repaid as at December 31, 2019. As of December 31, 2019 and June 30, 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: December 31, 2019 June 30, 2019 Exchange rate on balance sheet dates USD : AUD exchange rate 0.7030 0.7153 Average exchange rate for the period USD : AUD exchange rate 0.6847 0.7009 The exchange rates used to translate amounts in AUD into USD for the period ended December 31, 2018 are: 0.7046 as of the balance sheet date and 0.7248 average exchange rate for that period. Change in Accumulated Other Comprehensive Income (Loss) by component during the six months ended December 31, 2019 was as follows: Foreign Beginning balance, June 30, 2019 $ 1,066,998 Foreign currency translation loss (65,807 ) Ending balance, December 31, 2019 $ 1,001,191 Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 10 - Derivative Financial Instruments and Fair Value Measurements. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no cash equivalents as of December 31, 2019 or June 30, 2019. Patents Patents are stated at cost and classified as intangible assets and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any product costs as long as we are in the startup stage. Accordingly, as the Company’s products were and are not currently approved for market, all historical patent costs incurred through December 31, 2019 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency. Impairment of Long-Lived Assets In accordance with ASC 360-10, “ Long-lived assets,” Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of December 31, 2019 and June 30, 2019, the Company was owed $2,432 and $5,439, respectively, from the Australian Taxation Office. These amounts were fully collected subsequent to the balance sheet reporting dates. Derivative Instruments ASC Topic 815, Derivatives and Hedging Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “ Distinguishing Liabilities from Equity Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act (“TCJA”) was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017. On December 22, 2017, the SEC Staff Accounting Bulletin No. 118 (“SAB 118”) was issued, which allows a company to recognize provisional tax amounts when it does not have the necessary information available, prepared or analyzed, including computations, in reasonable detail to complete its accounting for the change in tax law. SAB 118 provides for a measurement of up to one year from the date of enactment. Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as an income tax benefit, in operations, upon receipt. During each of the six months ended December 31, 2019 and 2018, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $108,751 and $116,970, respectively, which is reflected as a tax benefit in the accompanying condensed consolidated statements of operations and comprehensive income (loss). Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. There was no cumulative effect of adoption on July 1, 2019. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. As of December 31, 2019, there were 1,975,059 warrants outstanding, 59,644 stock options and 15 convertible notes payable, which notes are convertible into approximately 10,200,000 shares of the Company’s common stock (based on the closing price on the last trading day of the quarter ended December 31, 2019). Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance. Such securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive. Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases On July 1, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Operating lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the condensed consolidated statements of operations. Recent Accounting Pronouncements We have reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management.

Going Concern

Going Concern	6 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 – GOING CONCERN The accompanying condensed consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the six months ended December 31, 2019, the Company had no revenues, had a net loss of $3,359,049 and had net cash used in operations of $1,142,877. Additionally, as of December 31, 2019, the Company had a working capital deficit, stockholders’ deficit and accumulated deficit of $5,693,527, $5,671,985 and $54,400,096, respectively. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful.

Due to Former Director - Relate

Due to Former Director - Related Party	6 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Due to Former Director - Related Party	NOTE 3 – DUE TO FORMER DIRECTOR - RELATED PARTY Due to director - related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amount owed the former director at December 31, 2019 and June 30, 2019 is $31,257 and $31,164, respectively. The Company plans to repay the notes as its cash resources allow.

Loans and Notes Payable

Loans and Notes Payable	6 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Loans and Notes Payable	NOTE 4 – LOANS AND NOTES PAYABLE Loans from Directors and Officer - Related Parties Loans from the Company’s directors and officer at December 31, 2019 and June 30, 2019 were $52,022 and $51,867, respectively. The loans bear no interest and are all payable on demand. The Company did not repay any amount on these loans during the six months ended December 31, 2019.

Convertible Notes

Convertible Notes	6 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Convertible Notes	NOTE 5 – CONVERTIBLE NOTES The Company’s convertible notes outstanding at December 31, 2019 were as follows: Convertible notes and debenture $ 2,016,365 Unamortized discounts (415,712 ) Accrued interest 182,581 Premiums 1,151,106 Convertible notes, net $ 2,934,340 Eagle Equities Financing Agreements December 29, 2017 Securities Purchase Agreement The Company entered into an executory contract on December 29, 2017, whereby the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “December 2017 Eagle Note”) from the Company in the aggregate principal amount of $532,435, with principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities at any time. The transactions closed on January 2, 2018. The December 2017 Eagle Note contains an original issue discount of $25,354 such that the purchase price was $507,081. The maturity date of the December 2017 Eagle Note was December 29, 2018. The Company is currently in discussions with Eagle Equities to extend the maturity date. The December 2017 Eagle Note bears interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of the Company’s common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time. The Company has recorded $9,630 of accrued interest for the December 2017 Eagle Note and total principal outstanding as of December 31, 2019 under the December 2017 Eagle Note was $13,865 following conversion of $158,100 of principal and $22,478 of accrued interest during the six months to December 31, 2019. Eagle Equities has the option to convert all or any amount of the principal face amount of the December 2017 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price of the Company’s common stock as reported on the OTCQB for the ten prior trading days, including the day upon which the Company receives a notice of conversion from Eagle Equities. The note is treated as stock settled debt under ASC 480 and accordingly the Company recorded a $354,956 put premium of which of which $240,313 was released to additional paid in capital following conversion of $360,470 of principal during the fiscal year to June 30, 2019, and a further $105,400 was released to additional paid in capital following conversion of $158,100 of principal during the six months to December 31, 2019. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. July 13, 2018 Securities Purchase Agreement Effective July 13, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “July 2018 Note”) from the Company in the aggregate principal amount of $75,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six month anniversary of the July 2018 Eagle Note. The transaction closed on July 16, 2018 and on July 19, 2018 the Company received proceeds of $71,250 as $3,750 was paid directly to legal fees. The maturity date of the July 2018 Eagle Note was July 13, 2019. The Company is currently in discussions with Eagle Equities to extend the maturity date. The July 2018 Eagle Note bears interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of the Company’s common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal face amount of the July 2018 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price of the Company’s common stock for the ten prior trading days, including the day upon which the Company receives a notice of conversion, subject to adjustment in certain events. Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The July 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $50,000 put premium. The Company has recorded $14,860 of accrued interest and the total principal outstanding under the July 2018 Eagle Note was $75,000 as of December 31, 2019. The Company had the right to prepay the July 2018 Eagle Note with certain penalties until January 9, 2019. No prepayment was made as of such date. As a result, the July 2018 Eagle Note is now convertible. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. August 29, 2018 Securities Purchase Agreement Effective August 29, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “August 2018 Eagle Note”) from the Company in the aggregate principal amount of $105,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six-month anniversary of the August 2018 Eagle Note. The transactions contemplated by the agreement closed on August 30, 2018. The maturity date of the August 29, 2018 Eagle Note was August 2019. The Company is currently in discussions with Eagle Equities to extend the maturity date. The August 2018 Eagle Note bears interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of the Company’s common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the August 2018 Eagle Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal face amount of the August 2018 Eagle Note, at any time, into shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price (the “Closing Bid Price”) of the Company’s common stock as reported on the OTC Markets quotation system for the ten prior trading days, including the day upon which the Company receives a notice of conversion from Eagle Equities (the “Conversion Price”). However, in the event that the Company’s common stock is restricted by the DTC for any reason, the Conversion Price shall be lowered to 50% of the lowest Closing Bid Price for the duration of such restriction. If the Company fails to maintain a reserve of shares of its common stock at least four times the number of shares issuable upon conversion of the August 2018 Eagle Note for at least 60 days after the issuance of the August 28, 2018 Eagle Note, the conversion discount shall be increased by 10%. Notwithstanding the foregoing, Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The August 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $70,000 put premium. The Company has recorded $19,746 of accrued interest and the total principal outstanding under the August 2018 Eagle Note was $105,000 as of December 31, 2019. The Company had the right to prepay the August 2018 Eagle Note with certain penalties until February 25, 2019. No prepayment was made as of such date. As a result, the August 2018 Eagle Note is now convertible. Upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% per annum or at the highest rate permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. October 2, 2018 Securities Purchase Agreement Effective October 2, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “October 2018 Eagle Note”) from the Company in the aggregate principal amount of $210,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six-month anniversary of the October 2018 Eagle Note. The transactions contemplated by the purchase agreement closed on October 3, 2018. Pursuant to the terms of the purchase agreement, Eagle Equities deducted $10,000 from the principal payment due under the October 2018 Eagle Note, at the time of closing, to be applied to its legal expenses. The maturity date of the October 2018 Eagle Note was October 2, 2019. The October 2018 Eagle Note shall bear interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the October 2018 Eagle Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal amount of the October 2018 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price of the Company’s common stock for the ten prior trading days, including the day upon which the Company receives a notice of conversion, subject to adjustment in certain events. Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The October 2, 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $140,000 put premium. The Company has recorded $29,227 of accrued interest and the total principal outstanding under the October 2018 Eagle Note was $210,000 as of December 31, 2019. The Company had the right to prepay the October 2018 Eagle Note with certain penalties until December 31, 2019. No prepayment has been made as of such date. As a result, the October 2018 Eagle Note is now convertible. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. November 30, 2018 Securities Purchase Agreement Effective November 30, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “November 2018 Eagle Note”) from the Company in the aggregate principal amount of $105,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six-month anniversary of the November 2018 Eagle Note. The transactions contemplated by the purchase agreement closed on December 3, 2018. Pursuant to the terms of the purchase agreement, Eagle Equities deducted $5,000 from the principal payment due under the November 2018 Eagle Note, at the time of closing, to be applied to its legal expenses. The maturity date of the November 2018 Eagle Note was November 30, 2019. The November 2018 Eagle Note shall bear interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the November 2018 Eagle Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal amount of the November 2018 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 61% of the lowest closing bid price (the “Closing Bid Price”) of the Company’s common stock as reported on the OTC Markets Group, Inc. quotation system for the ten prior trading days, including the day upon which the Company receives a notice of conversion from Eagle Equities (the “Conversion Price”). However, in the event that the Company’s common stock is restricted by the Depository Trust Company for any reason, the Conversion Price shall be lowered to 51% of the lowest Closing Bid Price for the duration of such restriction. If the Company fails to maintain a reserve of shares of its common stock at least two and a half times the number of shares issuable upon conversion of the November 2018 Eagle Note for at least 60 days after the issuance of the November 2018 Eagle Note, the conversion discount shall be increased by 10%. Notwithstanding the foregoing, Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The November 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded a $67,131 put premium. The Company has recorded $10,540 of accrued interest and the total principal outstanding under the November 2018 Eagle Note was $105,000 as of December 31, 2019. The November 2018 Eagle Note may be prepaid with certain penalties by the Company until May 29, 2019. No prepayment has been made as of December 31, 2019. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. December 24, 2018 Securities Purchase Agreement Effective December 24, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “December 2018 Eagle Note”) from the Company in the aggregate principal amount of $126,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Eagle Equities any time after the six-month anniversary of the December 2018 Eagle Note. The transactions contemplated by the purchase agreement closed on December 24, 2018. Pursuant to the terms of the purchase agreement, Eagle Equities deducted $6,000 from the principal payment due under the December 2018 Eagle Note, at the time of closing, to be applied to its legal expenses. The Company used the net proceeds from the December 2018 Eagle Note to repay an outstanding convertible promissory note before such note became convertible. The maturity date of the December 2018 Eagle Note was December 24, 2019. The December 2018 Eagle Note shall bear interest at a rate of 8% per annum, which interest shall be paid by the Company to Eagle Equities in shares of common stock upon receipt of a notice of conversion by the Company from Eagle Equities at any time after the six-month anniversary of the December 2018 Eagle Note. Additionally, Eagle Equities has the option to convert all or any amount of the principal amount of the December 2018 Eagle Note, at any time, for shares of the Company’s common stock at a price equal to 61% of the lowest closing bid price (the “Closing Bid Price”) of the Company’s common stock as reported on the OTC Markets Group, Inc. quotation system for the ten prior trading days, including the day upon which the Company receives a notice of conversion from Eagle Equities (the “Conversion Price”). However, in the event that the Company’s common stock is restricted by the Depository Trust Company for any reason, the Conversion Price shall be lowered to 51% of the lowest Closing Bid Price for the duration of such restriction. If the Company fails to maintain a reserve of shares of its common stock at least two and a half times the number of shares issuable upon conversion of the December 2018 Eagle Note for at least 60 days after the issuance of the December 2018 Eagle Note, the conversion discount shall be increased by 10%. Notwithstanding the foregoing, Eagle Equities shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Eagle Equities and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The December 2018 Eagle Note is treated as stock settled debt under ASC 480 and accordingly, the Company recorded an $80,557 put premium. The Company has recorded $10,688 of accrued interest and the total principal outstanding under the November 2018 Eagle Note was $126,000 as of December 31, 2019. The December 2018 Eagle Note may be prepaid with certain penalties until June 22, 2019. No prepayment has been made as of December 31, 2019. Upon an event of default, principal and accrued interest will become immediately due and payable under the notes. Additionally, upon an event of default, both notes will accrue interest at a default interest rate of 24% per annum or the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. The total principal amount outstanding under the above Eagle Equities financing agreements, specifically the December 29, 2017, the July 13, 2018, the August 29, 2018, the October 2, 2018, the November 30, 2018 and the December 24, 2018 agreements was $634,865 as of December 31, 2019 and accrued interest totaled $94,691. GS Capital Financing Agreements October 2, 2018 Securities Purchase Agreement Effective October 2, 2018, the Company entered into a securities purchase agreement with GS Capital, pursuant to which GS Capital purchased two 8% unsecured convertible redeemable notes (the “October 2, 2018 GS Notes”) from the Company in the aggregate principal amount of $212,000, such principal and the interest thereon convertible into shares of the Company’s common stock. The purchase price of $106,000 of the first note (the “October 2018 GS Note”) was paid in cash by GS Capital on October 3, 2018. After payment of certain legal fees and expenses, net proceeds to the Company from the October 2018 GS Note totaled $100,700. The purchase price of $106,000 of the second note (the “October 2, 2018 GS Back End Note”) was initially paid for by GS Capital issuing to the Company an offsetting $106,000 collateralized secured note (the “October 2, 2018 GS Secured Note”). The terms of the October 2018 GS Back End Note require cash funding prior to any conversion thereunder, and such cash funding shall occur on or before June 2, 2019. Both the October 2, 2018 GS Note and the October 2, 2018 GS Back End Note, which was funded on February 27, 2019, mature on October 2, 2019, upon which any outstanding principal and interest thereon is due and payable. The amounts cash funded plus accrued interest under both the October 2018 GS Note and the October 2018 GS Back End Note are convertibles into shares of the Company’s common stock, at any time after April 2, 2019, at a conversion price for each share of common stock equal to 61% of the lowest closing bid price of the Company’s common stock for the ten prior trading days including the day upon which a notice of conversion is received by the Company from GS Capital, subject to adjustment in certain events. GS Capital shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by GS Capital and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. The October 2018 GS Note and the October 2018 GS Back End Note are treated as stock settled debt under ASC 480 and accordingly, the Company recorded a total $67,771 put premium for each note of which $44,690 was released in respect of the October 2018 GS Note in the fiscal year ended June 30, 2019, and a further $22,901 was released in the six months ended December 31, 2019 following full conversion of the October 2018 GS Note resulting from conversion of the remaining principal balance of $35,820 and $2,434 in accrued interest. $31,903 of the put premium was released in respect of the October 2018 GS Back-End Note during the six months to December 31, 2019 following conversion $49,900 of the principal balance. The total principal amount outstanding under the October 2018 GS Note, was $35,820 and accrued interest thereunder totaled $7,813 as of June 30, 2019 and was fully converted as of December 31, 2019 (see Note 6 – Stockholders’ Deficit). The maturity date of the October 2, 2018 GS Back-Note was October 2019. The total principal balance under the October 2018 GS Back-End Note, was $106,000 and accrued interest thereunder totaled $5,715 as of June 30, 2019 and the principal balance was $56,100 and accrued interest totaled $11,814 as of December 31, 2019 (see Note 6 – Stockholders’ Deficit). The October 2, 2018 GS Notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. Consulting Agreement On August 10, 2017, the Company entered into a consulting agreement, retroactive to May 16, 2017, with a certain consultant, pursuant to which the consultant agreed to provide certain consulting and business advisory services in exchange for a $310,000 junior subordinated convertible note. The maturity date of the August 10, 2017 Convertible Note is August 2019.The note accrues interest at a rate of 10% per annum and is convertible into common stock at the lesser of $750 or 65% of the three lowest trades in the ten trading days prior to the conversion. The note was fully earned upon signing the agreement and matures on August 10, 2019. The Company accrued $155,000 related to this expense at June 30, 2017 and recorded the remaining $155,000 related to this expense in fiscal year 2018. Upon an event of default, principal and accrued interest will become immediately due and payable under the note. Additionally, upon an event of default, at the election of the holder, the note would accrue interest at a default interest rate of 18% per annum or the highest rate of interest permitted by law. The consulting agreement had a three-month term and expired on August 16, 2017. An aggregate total of $578,212 of this note was bifurcated with the embedded conversion option recorded as a derivative liability at fair value. During the year ended June 30, 2018, the consultant converted $140,000 of principal and $10,764 of interest. During the year ended June 30, 2019, the consultant converted an additional $161,000 of principal and $19,418 of interest, such that the remaining principal outstanding and accrued interest under this note as of December 31, 2019 was $9,000 and $26,653, respectively. Redstart Holdings Finance Agreements May 23, 2019 Securities Purchase Agreement Effective May 23, 2019, the Company issued a convertible promissory note (the “May 23 Redstart Holdings Note”) to Redstart Holdings Corp (“Redstart Holdings”) in the aggregate principal amount of $133,000, with principal and the interest thereon convertible into shares of the Company’s common stock at the option of Redstart Holdings any time after 180 days of issuance. At the time of closing on May 31, 2019, Redstart Holdings deducted $3,000 from the principal payment due under the May 2019 Redstart Holdings Note to be applied to its legal expenses, such that the Company received aggregate net proceeds of $130,000 at closing. The maturity date of the May 2019 Redstart Holdings Note is May 23, 2020 and bears interest at a rate of 8% per annum. Additionally, Redstart Holdings has the option to convert all or any amount of the principal face amount of the May 2019 Redstart Note, starting on November 19, 2019 at a conversion price subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $50.00, the conversion price shall be the greater of 65% of the Market Price (“Variable Conversion Price”) and $32.50. In the event Market Price is less than $50.00, the conversion price shall be the Variable Conversion Price. As defined in the May 2019 Redstart Holdings Note, the “Market Price” shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Redstart Holdings on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Redstart Holdings. Notwithstanding the foregoing, Redstart Holdings shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Redstart Holdings and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. An aggregate total of $166,564 of this note was bifurcated with the embedded conversion option recorded as a derivative liability at fair value (See Note 10 - Derivative Financial Instruments and Fair Value Measurements). The Company had the right to prepay the May 2019 Redstart Holdings Note until November 19, 2019. If the May 2019 Redstart Holdings Note was prepaid within 90 days of the issuance date, then the prepayment premium shall be 115% of the face amount plus any accrued interest; if the May 2019 Redstart Holdings Note was prepaid after 91 days from the issuance date, but prior to 121 days from the issuance date, then the prepayment premium shall be 120% of the face amount plus any accrued interest; and if the May 2019 Redstart Holdings Note was prepaid after 121 days from the issuance date, but prior to 150 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest; and if the May 2019 Redstart Holdings Note was prepaid after 151 days from the issuance date, but prior to 180 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest. The May 23, 2019 Redstart Holdings Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. The total principal amount outstanding and accrued interest under the above Redstart Holdings financing agreement, specifically the May 23, 2019 agreement at June 30, 2019 was $133,000 and $1,137 respectively and as of December 31, 2019 total principal amount outstanding and accrued interest totaled $86,400 and $6,322 respectively following conversion of $46,600 of the principal balance during the six months to December 31, 2019. The Company also recorded an amount of $18,266 of debt discount amortization related to the conversions during the six months to December 31, 2019. Power Up Lending Group Financing Agreements July 3, 2019 Securities Purchase Agreement Effective July 3, 2019, the Company entered into a securities purchase agreement with Power Up Lending Group Ltd. (“Power Up”), pursuant to which Power Up purchased a convertible promissory note (the “July 3, 2019 Power Up Note”) from the Company in the aggregate principal amount of $78,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Power Up. The transaction closed on July 3, 2019 and the Company received payment on July 8, 2019 in the amount of $78,000, of which $2,500 was paid directly toward legal fees and $500 to Power Up for due diligence fees resulting in net cash proceeds of $75,000. The maturity date of the July 3, 2019 Power Up Note is July 3, 2020. The July 3, 2019, Power Up Note bears interest at a rate of 8% per annum, which interest may be paid by the Company to Power Up in shares of the Company’s common stock, but shall not be payable until the July 3, 2019 Power Up Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. Additionally, Power Up has the option to convert all or any amount of the principal face amount of the July 3, 2019 Power Up Note, starting on December 30, 2019 and ending on the later of the maturity date or the date the Default Amount, which is an amount equal to 150% of an amount equal to the then outstanding principal amount of the July 3, 2019 Power Up Note plus any interest accrued, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the July 3, 2019 Power Up Note shall be $3.25, subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $5.00, the conversion price shall be the greater of 65% of the Market Price (“Variable Conversion Price”) and $3.25. In the event Market Price is less than $5.00, the conversion price shall be the Variable Conversion Price. As defined in the July 3, 2019 Power Up Note, the “Market Price” shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. An aggregate total of $155,904 of this note was bifurcated with the embedded conversion option recorded as a derivative liability at fair value (See Note 10 - Derivative Financial Instruments and Fair Value Measurements). The July 3, 2019 Power Up Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. The total principal amount outstanding under the above Power Up financing agreement, specifically the July 3, 2019 Power Up Note, was $78,00

Stockholders' Deficit

Stockholders' Deficit	6 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Stockholders' Deficit	NOTE 6 – STOCKHOLDERS’ DEFICIT On June 24, 2019, the Company effected a one-for-five hundred (1:500) reverse stock split whereby the Company (i) decreased the number of authorized shares of common stock, $0.001 par value per share, to 100,000,000 and (ii) decreased by a ratio of one-for-five hundred (1:500) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest period, presented in the consolidated financial statements to reflect the reverse stock split. Preferred Stock: The total number of shares of preferred stock that the Company is authorized to issue is 1,500,005, $0.01 par value per share. These preferred shares have no rights to dividends, profit sharing or liquidation preferences. Of the total preferred shares authorized, 500,000 have been designated as Series A Preferred Stock (“Series A Preferred Stock”), pursuant to the Certificate of Designation filed with the Secretary of State of the State of Delaware on December 9, 2014. James Nathanielsz, the Company’s Chief Executive Officer beneficially owns all of the shares of Series A Preferred Stock via North Horizon Pty Ltd., which entitles him, as a holder of Series A Preferred Stock, to vote on all matters submitted or required to be submitted to a vote of the Company’s stockholders, except election and removal of directors, and each share of Series A Preferred Stock entitles him to two votes per share of Series A Preferred Stock. North Horizon Pty Ltd. is a Nathanielsz Family Trust. Mr. James Nathanielsz, the Chief Executive Officer and a director of our Company, has voting and investment power over these shares. 500,000 shares of Series A Preferred Stock are issued and outstanding as of December 31, 2019. Of the total preferred shares authorized, pursuant to the Certificate of Designation filed with the Secretary of State of the State of Delaware on June 16, 2015, up to five shares have been designated as Series B Preferred Stock (“Series B Preferred Stock”). Each holder of outstanding shares of Series B Preferred Stock is entitled to voting power equivalent to the number of votes equal to the total number of shares of common stock outstanding as of the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company and entitled to vote on all matters submitted or required to be submitted to a vote of the stockholders of the Company. One share of Series B Preferred Stock is issued and outstanding as of December 31, 2019. Mr. Nathanielsz directly beneficially owns such one share of Series B Preferred Stock. Common Stock: Shares issued for conversion of convertible debt During the six months ended December 31, 2019, the Company issued 1,246,859 shares of its common stock at an average contractual conversion price of $0.3575, ranging from $0.067 to $0.906, as a result of the conversion of principal and interest in the aggregate amount of $318,768 underlying certain outstanding convertible notes converted during such period. The total recorded to equity was $343,179. Notes totaling $46,600 contained bifurcated embedded conversion option derivatives. Accordingly, the fair market value of the shares issued was $71,011 resulting in a loss on extinguishment at the time of conversion of $24,411, $44,587 of derivative fair value was recorded as a gain on extinguishment at the time of conversion. The Company reclassified $160,205 in put premiums to additional paid in capital following conversions during the six months ended December 31, 2019. The Company has 77,292,139 shares of its common stock reserved for future issuances based on lender reserve requirements pursuant to underlying financing agreements at December 31, 2019. Shares issued for services On July 19, 2019, the Company entered into an agreement with a certain consultant to provide services over a two-month period beginning July 1, 2019 and ending September 1, 2019 in exchange for 20,000 shares of the Company’s common stock. On July 19, 2019, the Company issued the 20,000 shares of the Company’s common stock valued at $1.99 per share; being the closing price of the stock on the date of the agreement, to such consultant, or $39,800, which will be amortized over the term of the agreement. The Company recorded $39,800 of consulting expense with respect to such shares of its common stock during the six months ended December 31, 2019. Restricted Stock Units Pursuant to employment agreements dated in May 2019 (see Note 8), the Company granted an aggregate of 78,000 and 39,000 restricted stock unit to the Company’s Chief Executive Officer and Chief Scientific Officer, respectively. The total 117,000 restricted stock units are subject to vesting terms as defined in the employment agreements. The 117,000 restricted stock units were valued at the fair value of $4.25 per unit or $497,240 based on the quoted trading price on the date of grant. During the six months ended December 31, 2019, the Company recognized stock-based compensation of $108,771 related to vested restricted stock units. There were $357,392 unrecognized restricted stock units expense as of December 31, 2019. Warrants: In connection with the issuance of the August 2019 Auctus Note, the Company issued common stock purchase warrants to Auctus to purchase 450,000 shares of the Company’s common stock (the “First Warrant”) as a commitment fee upon the terms and subject to the limitations and conditions set forth in such First Warrant at an “Exercise Price” of $2.25. In connection with the issuance of the Note, the Company shall issue a common stock purchase warrant to Buyer to purchase 300,000 shares of the Company’s common stock (the “Second Warrant”) as a commitment fee upon the terms and subject to the limitations and conditions set forth in such Second Warrant at an “Exercise Price” of $3.33. In connection with the issuance of the Note, the Company shall issue a common stock purchase warrant to Buyer to purchase 225,000 shares of the Company’s common stock (the “Third Warrant”) as a commitment fee upon the terms and subject to the limitations and conditions set forth in such Third Warrant at an “Exercise Price” of $4.50. The First Warrant, Second Warrant, and Third Warrant shall collectively be referred as the “Warrants”. The Warrants have an “Exercise Period” of five years form the date of issuance being August 30, 2019 (see Note 5). On September 10, 2019, the Company entered into an agreement with a certain consultant to provide services over a three-month period beginning September 10, 2019 and ending December 10, 2019 in exchange for 1,000,000 warrants to purchase the Company’s common stock at $2.00 per share with an expiry date of September 10, 2022. The Fair Market Value of the warrants was $984,810 on the date of grant as calculated under the Black Scholes Option Pricing model. The Company recorded $984,810 of share based compensation expenses with respect to the grant of such warrants during the six months ended December 31, 2019. As of December 31, 2019, there were 1,975,059 warrants outstanding and exercisable with expiration dates commencing May 2020 and continuing through August 2024, with a weighted average exercise price per share of $2.69. Options: As of December 31, 2019, the Company had entered into agreements to grant options to purchase 59,644 shares of its common stock, with a weighted average exercise price per share of $76.37. Pursuant to employment agreements dated in May 2019 (see Note 8), the Company granted options to purchase 39,000 and 19,500 shares of the Company’s common stock to the Company’s Chief Executive Officer and Chief Scientific Officer, respectively. The total 58,500 options have a term of 10 years from the date of grant and exercise price ranging from $4.25 to $4.675 per share. 1/3rd of these options shall vest every successive one-year anniversary, provided, that on each such vesting date, the Chief Executive Officer and Chief Scientific Officer are employed by the Company and subject to the other provisions of the employment agreement. The 58,500 stock options were valued using a Black-Scholes model with the following assumptions: stock price at valuation date of $4.25 based on quoted trading price on date of grant, exercise price of $4.65, dividend yield of zero, years to maturity of 10.00, a risk free rate of 2.42%, and expected volatility 268% for a total value of $248,620. During the six months ended December 31, 2019, the Company recognized stock-based compensation of $41,437 related to vested stock options. There was $196,824 of unvested stock options expense as of December 31, 2019 that will be recognized in future periods. No stock options were issued during the six months ended December 31, 2019.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 7 – COMMITMENTS AND CONTINGENCIES Legal Matters A complaint against us, dated September 26, 2019, has been filed by Foley Shechter Ablovatskiy (“Foley Shechter”), our former counsel, seeking $151,031.50 in legal fees, in addition to interest and costs of suit. The Company believes these claims to be unfounded and is vigorously defending itself. To that end, the Company filed a motion to dismiss certain counts of the complaint, with prejudice. That motion remains pending with the Supreme Court of the State of New York, County of New York. Upon resolution of the motion, the Company shall file an answer, together with affirmative defenses and counterclaims. The counterclaims shall include, without limitation, malpractice claims, arising out of Foley Shechter’s grossly negligent mishandling of certain transactions and excessive billing related thereto. Certain amounts related to this claim are included in accounts payable and accrued expenses in the accompanying Financial Statements. Regal Consulting, LLC (“Regal”) initiated litigation against the Company in Clark County District Court, Nevada. The Court entered a default judgment against the Company on December 17, 2019. However, Regal, through counsel, has agreed to execute a stipulation to vacate the default and proceed with litigation. Regal is demanding approximately $400,000 and 60,000 shares of the Company’s common stock as payment for services that Regal purports to have performed. The Company intends to vigorously defend itself against Regal’s unsubstantiated claims and no loss contingency can be estimated at this time. In addition to the above, from time to time, we may be involved in litigation in the ordinary course of business. Other than as set forth above, we are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. Other than as set forth above, to our knowledge, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of our executive officers or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or any of our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect. IRS Liability As part of its requirement for having a foreign operating subsidiary, the Company’s parent U.S. entity is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $10,000 per year, or $30,000 in total, plus accrued interest, such penalty and interest having been accrued and is included in the Accrued expenses and other payable figure in the Balance Sheet. The Company recorded the penalties for all three years during the year ended June 30, 2018 and is negotiating a payment plan. The Company is current on all subsequent filings. Operating Agreements In November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the “University”) whereby the Company and the University co-owned the intellectual property relating to the Company’s pro-enzyme formulations. In June 2012, the Company and the University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property while agreeing to pay royalties of 2% of net revenues to the University. Additionally, the Company agreed to pay 5% of each and every license agreement subscribed for. The contract is cancellable at any time by either party. To date, no amounts are owed under the agreement. Operating Leases On May 5, 2016, the Company entered into a new five-year operating lease agreement with a Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors, with monthly rent of $3,606 AUD or $2,469 USD, inclusive of GST (See Note 8 – Related Party Transactions). ROU is summarized below: December 31, 2019 Office lease ROU $ 48,662 Less accumulated reduction (13,271 ) Balance of ROU asset as of December 31, 2019 $ 35,391 Operating lease liability related to the ROU asset is summarized below: December 31, 2019 Office lease liability $ 48,662 Reduction of lease liability (11,352 ) Total 37,310 Less: current portion (14,216 ) Long term portion of lease liability as of December 31, 2019 $ 23,094 Future Minimum lease payments under non-cancelable operating lease at December 31, 2019 are as follows: Remainder Fiscal Year 2020 $ 15,120 Year 2021 23,119 Total 38,239 Imputed interest (929 ) Total operating lease liability $ 37,310 Amatsigroup Agreement The Company entered into a Manufacturing Services Agreement (the “MSA”) and Quality Assurance Agreement (the “QAA”), each with an effective date of August 12, 2016, with Amatsigroup NV (“Amatsigroup”), formerly known as Q-Biologicals, NV, a contract manufacturing organization located in Belgium. Pursuant to the MSA, Amatsigroup produces certain drug substances and products containing certain enzymes for the Company at its facility in Belgium. The Company uses these substances and products for development purposes, including but not limited to future clinical trials. The MSA contemplates payment to Amatsigroup pursuant to a pre-determined fee schedule based on the completion of certain milestones that depend on our manufacturing requirements and final batch yield. The Company anticipates that its payments to Amatsigroup under the MSA will range between $2.5 million and $5.0 million over three years, when the finished drug product is manufactured and released for clinical trials. The Company has spent a total of $1,689,146 of costs to date under this contract of which $1,689,146 was expensed in prior years. The MSA shall continue for a term of three years unless extended by mutual agreement in writing. The Company can terminate the MSA early for any reason upon the required notice period, however, in such event, the pre-payment paid upon signing the MSA is considered non-refundable. Each party to the MSA shall have the right to terminate the MSA by written notice to the other party if the other party commits a material breach of the MSA (subject to a 30-day cure period). The QAA sets forth the parties respective obligations and responsibilities relating to the manufacturing and testing of the products under the MSA. The agreements with Amatsigroup contain certain customary representations, warranties and limitations of liabilities, and confidentiality and indemnity obligations. Collaboration Agreement On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaen (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 52,000 Euros ($59,508 USD) in year one and a maximum of 40,000 Euros ($45,775 USD) in year two. Additionally, in exchange for full ownership of the intellectual property the Company agreed to pay royalties of 2% of net revenues to the University.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 8 – RELATED PARTY TRANSACTIONS Since its inception, the Company has conducted transactions with its directors and entities related to such directors. These transactions have included the following: As of December 31, 2019 and June 30, 2019, the Company owed a current and a former director a total of $52,022 and $51,867, respectively, for money loaned to the Company throughout the years. The total loans balance owed at December 31, 2019 and June 30, 2019 is not interest bearing (See Note 4 – Loans and Notes Payable). As of December 31, 2019 and June 30, 2019, the Company owed its former director a total of $31,257 and $31,164, respectively, related to expenses paid on behalf of the Company related to corporate startup costs and intellectual property (See Note 3 – Due to Former Director – Related Party). Effective May 5, 2016, the Company entered into an agreement for the lease of its principal executive offices with North Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors. The lease has a five-year term and provides for annual rental payments of $42,048 AUD or $28,790 USD, which includes $3,823 AUD or $2,618 USD of goods and service tax for total payments of $210,242 AUD or $143,953 USD during the term of the lease. As of December 31, 2019, total payments of $59,943AUD or $41,044 USD remain on the lease. (See Note 7 – Commitments and Contingencies) The Company and Mr. Nathanielsz entered into an employment agreement as of February 25, 2015 (the “Nathanielsz Employment Agreement”) setting forth the terms and conditions of Mr. Nathanielsz employment as the Company’s President and Chief Executive Officer. The Nathanielsz Employment Agreement was scheduled to expire on February 25, 2019; however, the term of the Nathanielsz Employment Agreement automatically renews for successive one-year periods unless either party provides 30 days’ prior written notice of its intent not to renew. The Nathanielsz Employment Agreement continues in effect as of December 31, 2019. The Nathanielsz Employment Agreement provides Mr. Nathanielsz with a base salary of $25,000 AUD per month ($300,000 AUD annually or $205,680 USD) and a monthly contribution to Mr. Nathanielsz’s pension equal to 9.5% of his monthly salary. Mr. Nathanielsz has the ability to convert any accrued but unpaid salary into common stock at the end of each fiscal year at a conversion price to be determined by Mr. Nathanielsz and the Company, which will in no event be lower than par value or higher than the closing bid price on the date of conversion. Pursuant to the Nathanielsz Employment Agreement, Mr. Nathanielsz is entitled to an annual discretionary bonus in an amount up to 200% of his annual base salary, which bonus shall be determined by the Company’s board of directors based upon the performance of the Company. On March 16, 2018, the Company’s board of directors approved an increase of Mr. Nathanielsz’s annual base salary from $300,000 AUD ($205,680 USD) to $400,000 AUD ($274,240 USD), effective February 2018. Mr. Nathanielsz’s wife, Sylvia Nathanielsz, is and has been a non-executive part-time employee of the Company since October 2015. Effective February 1, 2018. Mrs. Nathanielsz receives an annual salary of $82,272 and is entitled to customary benefits. Pursuant to a February 25, 2016 board resolution, James Nathanielsz shall be paid $4,481 AUD ($3,205 USD), on a monthly basis for the purpose of acquiring and maintaining an automobile. For the six months ended December 31, 2019, a total of $21,378 AUD ($14,638 USD) in payments have been made with respect to Mr. Nathanielsz’s car allowance. Pursuant to the approval of the Company’s board of directors, on March 16, 2018, Mr. Nathanielsz was granted a $300,000 AUD ($210,090 USD) bonus for accomplishments achieved while serving as the Company’s Chief Executive Officer during the fiscal year ended June 30, 2018. A total of $80,046 AUD ($56,056 USD) in payments were made in the year ended June 30, 2018. During the nine months ended March 31, 2019, an additional $219,954 AUD ($154,100 USD) was paid. Such bonus was fully paid to Mr. Nathanielsz as of June 30, 2019. Pursuant to the approval of the Company’s board of directors, on May 14, 2019, Mr. Nathanielsz was granted a $460,000 AUD ($315,376 USD) bonus for accomplishments achieved while serving as the Company’s Chief Executive Officer during the fiscal year ended June 30, 2019 with $200,000 AUD ($137,120 USD) of such bonus payable by the Corporation to the CEO throughout the Corporation’s 2019 fiscal year as the Corporation’s cash resources allow, with the remaining $260,000 AUD ($178,256 USD) of such bonus to be deferred by the CEO until a future date when the Corporation’s cash resources allow for such payment, as agreed to by the CEO. A total of $90,000 AUD ($64,377 USD) in payments were made in the year ended June 30, 2019. A total of $137,620 AUD ($94,228 USD) in payments were made in the six months ended December 31, 2019, with $232,380 AUD ($163,363 USD) remaining due and payable. New Employment and Services Agreements with Management Amended and Restated Employment Agreement ― On May 14, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Employment Agreement (the “Employment Agreement”) with James Nathanielsz, the Company’s Chief Executive Officer, Chairman, acting Chief Financial Officer and a director, for a term of three years, subject to automatic one-year renewals, at an annual salary of $400,000 AUD. Pursuant to the Employment Agreement, Mr. Nathanielsz was granted options to purchase 39,000 shares of the Company’s common stock (the “Nathanielsz Options”), with an exercise price per share of $4.675 (110% of the closing market price of the Company’s common stock on May 14, 2019 (or $4.25), the date of approval of such grant by the Company’s board of directors), (ii) 39,000 restricted stock units of the Company (the “Initial Nathanielsz RSUs”), and (iii) an additional 39,000 restricted stock units of the Company (the “Additional Nathanielsz RSUs”). Such options and restricted stock units were granted pursuant to the 2019 Plan (as defined below) approved by the Company’s board of directors on the Effective Date. The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz’s continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz’s continued employment with the Company through the applicable vesting date: (i) 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the “CTA”) for PRP, the Company’s lead product candidate (“PRP”), for a First-In-Human study for PRP (the “Study”) in an applicable jurisdiction to be selected by the Company, (ii) 7,800 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7,800 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7,800 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company’s Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested restricted stock unit shall be settled by delivery to Mr. Nathanielsz of one share of the Company’s common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company’s board of directors and subject to the 2019 Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Employment Agreement), (ii) the date that is ten business days following the vesting of such restricted stock unit, (iii) the date of Mr. Nathanielsz’s death or Disability (as defined in the Employment Agreement), and (iv) Mr. Nathanielsz’s employment being terminated either by the Company without Cause or by Mr. Nathanielsz for Good Reason (each as defined in the Employment Agreement). In the event of a Change of Control, any unvested portion of the Nathanielsz Options and such restricted stock units shall vest immediately prior to such event. The 78,000 restricted stock units were valued at the fair value of $4.25 per unit or $331,500 based on the quoted trading price on the date of grant. The 39,000 stock options were valued using a Black-Scholes model with the following assumptions: stock price at valuation date of $4.25 based on quoted trading price on date of grant, exercise price of $4.65, dividend yield of zero, years to maturity of 10.00, a risk free rate of 2.42%, and expected volatility 268% for a total value of $165,747 (see Note 6 – Stockholders’ Deficit). Amended and Restated Services Agreement ― On the Effective Date, the Company also entered into an Amended and Restated Services Agreement (the “Services Agreement”) with Dr. Kenyon, the Company’s Chief Scientific Officer and a director, for a term of three years, subject to automatic one-year renewals, at an annual salary of $54,000 AUD. In connection with the execution of the Services Agreement, Dr. Kenyon was designated as an executive officer of the Company and assumed a more active executive role with the Company. Pursuant to the Services Agreement, Dr. Kenyon was granted options to purchase 19,500 shares of the Company’s common stock (the “Kenyon Options”), with an exercise price per share of $4.25 (100% of the closing market price of the Company’s common stock on May 14, 2019, the date of approval of such grant by the Company’s board of directors), (ii) 19,500 restricted stock units of the Company (the “Initial Kenyon RSUs”), and (iii) an additional 19,500 restricted stock units of the Company (the “Additional Kenyon RSUs”). Such options and restricted stock units were granted pursuant to the 2019 Plan (as defined below) approved by the Company’s board of directors on the Effective Date. The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon’s continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon’s continued employment with the Company through the applicable vesting date: (i) 4,875 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 4,875 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii) 4,875 of the Additional Kenyon RSUs shall vest upon the shares of the Company’s Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (iv) the remaining 4,875 of the Additional Kenyon RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested Kenyon RSU shall be settled by delivery to Mr. Kenyon of one share of the Company’s common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company’s board of directors and subject to the Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Services Agreement), (ii) the date that is ten business days following the vesting of such Kenyon RSU, (iii) the date of Dr. Kenyon’s death or Disability (as defined in the Services Agreement), and (iv) Dr. Kenyon’s employment being terminated either by the Company without Cause or by Dr. Kenyon for Good Reason (as defined in the Services Agreement). In the event of a Change of Control (as defined in the Services Agreement), 50% of any unvested portion of the Kenyon Options and the Kenyon RSUs shall vest immediately prior to such event. The 39,000 restricted stock units were valued at the fair value of $4.25 per unit or $165,750 based on the quoted trading price on the date of grant. The 19,500 stock options were valued using a Black-Scholes model with the following assumptions: stock price at valuation date of $4.25 based on quoted trading price on date of grant, exercise price of $4.25, dividend yield of zero, years to maturity of 10.00, a risk free rate of 2.42%, and expected volatility 268% for a total value of $82,873 (see Note 6 – Stockholders’ Deficit).

Concentrations and Risks

Concentrations and Risks	6 Months Ended
	Dec. 31, 2019
Risks and Uncertainties [Abstract]
Concentrations and Risks	NOTE 9 – CONCENTRATIONS AND RISKS Concentration of Credit Risk The Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through December 31, 2019. Receivable Concentration As of December 31, 2019 and June 30, 2019, the Company’s receivables were 100% related to reimbursements on GST taxes paid. Patent and Patent Concentration The Company has filed multiple patent applications relating to its lead product, PRP. The Company’s lead patent application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, Republic of Korea and India. In Brazil and Canada, the patent application remains under examination. In 2016 and early 2017, we filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016, entered national phase in July 2018 and another PCT application is currently entering national phase in August 2018. A third PCT application entered the national phase in October 2018. Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer. Foreign Operations As of December 31, 2019 and June 30, 2019, the Company’s operations are based in Camberwell, Australia, however the majority of research and development is being conducted in the European Union. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application with the European Medicines Agency as a small and medium-sized enterprise. As of December 31, 2019, there has been no activity within this entity.

Derivative Financial Instrument

Derivative Financial Instruments and Fair Value Measurements	6 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments and Fair Value Measurements	NOTE 10 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company had $216,400 of convertible debt, that contain embedded conversion options and is treated as derivative instruments outstanding at December 31, 2019. The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at December 31, 2019, the last trading day of the quarter ended December 31, 2019, was $0.38. Volatility, expected remaining term and risk free interest rates used to estimate the fair value of derivative liabilities at December 31, 2019 are indicated in the table that follows. The expected term is equal to the remaining term of the warrants or convertible instruments and the risk free rate is based upon rates for treasury securities with the same term. Convertible Debt Initial Valuations into during the six December 31, 2019 Volatility 227.82 % 227.82 % Expected Remaining Term (in years) 1 00.39 – 0.91 Risk Free Interest Rate 1.59 % 1.48% – 1.59 % Expected dividend yield None None Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2019: Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 924,744 $ — $ — $ 924,744 Total $ 924,744 $ — $ — $ 924,744 The following is a roll forward for the six months ended December 31, 2019 of the fair value liability of price adjustable derivative instruments: Fair Value of Liability for Derivative Instruments Balance at June 30, 2019 $ 698,264 Initial fair value of embedded conversion option derivative liability recorded as debt discount 115,000 Initial fair value of embedded conversion option derivative liability recorded as expense 93,125 Reductions due to conversions (44,588 ) Change in fair value included in statements of operations 62,943 Balance at December 31, 2019 $ 924,744

Subsequent Events

Subsequent Events	6 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 11 – SUBSEQUENT EVENTS Note Conversions From January 1, 2020 through the date of this filing , the Company issued 2,804,424 shares of its common stock at an average contractual conversion price of $0.1654, ranging from $0.0672 to $0.75, as a result of the conversion of principal and interest in the aggregate amount of $267,187 underlying certain outstanding convertible notes converted during such period. Notes totaling $82,500 contained bifurcated embedded conversion option derivatives. Accordingly the fair market value of shares issued was $228,863 resulting in a loss on extinguishment of $146,367. The Company reclassified $410,750 in put premiums to additional paid in capital following conversions from January 1, 2020 through the date of this filing. Increase in Authorized Common Stock On February 4, 2020 the Directors resolved to increase the Common Stock of the Company from 100,000,000 authorized shares to 1,000,000,000 authorized shares and believes that such number of authorized shares of Common Stock will be in the best interests of the Corporation and its stockholders because the Board believes that the availability of more shares of Common Stock for issuance will allow the Corporation greater flexibility in pursuing financing from investors, meeting business needs as they arise, taking advantage of favorable opportunities and responding to a changing corporate environment. The Company filed the necessary documents with the U.S. Securities and Exchange Commission on February 6, 2020 and at the date of this filing the increase in authorized shares to 1,000,000,000 has not yet been effected. January 7, 2020 Power Up Lending Group Securities Purchase Agreement Effective January 7, 2020, the Company entered into a securities purchase agreement with Power Up Lending Group Ltd. (“Power Up”), pursuant to which Power Up purchased a convertible promissory note (the “January 7, 2020 Power Up Note”) from the Company in the aggregate principal amount of $75,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Power Up. The transaction closed on January 7, 2020 and the Company received payment on January 13, 2020 in the amount of $72,000, net of $2,500 paid directly toward legal fees and $500 to Power Up for due diligence fees. The maturity date of the January 7, 2020 Power Up Note is January 7, 2021. The January 7, 2020, Power Up Note bears interest at a rate of 8% per annum, which interest may be paid by the Company to Power Up in shares of the Company’s common stock, but shall not be payable until the January 7, 2020 Power Up Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. Additionally, Power Up has the option to convert all or any amount of the principal face amount of the January 7, 2020 Power Up Note, starting on July 4, 2020 and ending on the later of the maturity date or the date the Default Amount, which is an amount equal to 150% of an amount equal to the then outstanding principal amount of the January 7, 2020 Power Up Note plus any interest accrued, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the January 7, 2020 Power Up Note shall be $3.05, subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $5.00, the conversion price shall be the greater of 65% of the Market Price (“Variable Conversion Price”) and $3.05. In the event Market Price is less than $5.00, the conversion price shall be the Variable Conversion Price. As defined in the January 7, 2020 Power Up Note, the “Market Price” shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. An aggregate total of $307,400 of this note was bifurcated with the embedded conversion option recorded as a derivative liability at fair value. The January 7, 2020 Power Up Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. January 7, 2020 Consulting Services Agreement On February 4, 2020, the Company entered into an agreement with a certain consultant in relation to services provided during the period ended December 31, 2019 whereby the Company agreed to issue 150,000 vested shares of the Company’s common stock to the consultant in satisfaction of those services. On February 4, 2020, the Company issued the 150,000 shares of the Company’s common stock valued at $0.14 per share; being the closing price of the stock on the date of the agreement, to such consultant, or $21,000, which amount was recorded as a share based expense in the financial statements for the six months ended December 31, 2019. January 13, 2020 Ader Alef Securities Purchase Agreements Effective January 13, 2020, the Company entered into a securities purchase agreement with Ader Alef, pursuant to which Ader Alef purchased a convertible promissory note (the “January 13, 2020 Ader Alef Note”) from the Company in the aggregate principal amount of $110,250, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of Ader Alef any time after the six month anniversary of the January 13, 2020 Ader Alef Note. The January 13, 2020 Ader Alef Note contains an original discount of $5,250. The transactions contemplated by the Ader Alef Securities Purchase Agreement closed on January 13, 2020. Pursuant to the terms of the Ader Alef Securities Purchase Agreement, Ader Alef deducted $5,000 from the principal payment due under the January 13, 2020 Ader Alef Note at the time of closing, to be applied to its legal expenses and the Company received net cash proceeds of $100,000 on January 15, 2020. The Company intends to use the net proceeds from the January 13, 2020 Ader Alef Note for general working capital purposes. The maturity date of the January 13, 2020 Ader Alef is January 13, 2021. The January 13, 2020 Ader Alef Note bears interest at a rate of 8% per annum, which interest may be paid by the Company to Ader Alef in shares of the Company’s common stock; but shall not be payable until the January 13, 2020 Ader Alef Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. Additionally, Ader Alef has the option to convert all or any amount of the principal face amount of the January 13, 2020 Ader Alef Note at any time from the date of issuance and ending on the later of the maturity date and the date the Default Amount, which is an amount between 112% and 135% of an amount equal to the then outstanding principal amount of the January 13, 2020 Ader Alef Note plus any interest accrued, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the January 13, 2020 Ader Alef Note during the first 6 months the January 13, 2020 Ader Alef Note is in effect shall be fixed at $2.50 and thereafter shall be equal to a 35% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, Ader Alef shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Ader Alef and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock which may be increased up to 9.99% upon 60 days prior written notice by the Ader Alef to the Company. The note is treated as stock settled debt under ASC 480 and accordingly the Company recorded a $59,365 put premium. The January 13, 2020 Ader Alef Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions. January 22, 2020 GS Capital Securities Purchase Agreements Effective January 22, 2020, the Company entered into a securities purchase agreement with GS Capital, pursuant to which GS Capital purchased a convertible promissory note (the “January 22, 2020 GS Note”) from the Company in the aggregate principal amount of $58,000, such principal and the interest thereon convertible into shares of the Company’s common stock at the option of GS Capital any time after the six month anniversary of the January 22, 2020 GS Capital Note. The January 22, 2020 GS Note contains an original discount of $3,500. The transactions contemplated by the GS Capital Securities Purchase Agreement closed on January 22, 2020. Pursuant to the terms of the GS Capital Securities Purchase Agreement, GS Capital deducted $2,500 from the principal payment due under the January 22, 2020 GW Note, at the time of closing, to be applied to its legal expenses and received net cash proceeds of $52,000 on January 28, 2020. The Company intends to use the net proceeds from the January 22, 2020 GW Note for general working capital purposes. The maturity date of the January 22, 2020 GS Capital is January 22, 2021. The January 22, 2020 GS Capital Note bears interest at a rate of 10% per annum, which interest may be paid by the Company to GS Capital in shares of the Company’s common stock; but shall not be payable until the January 22, 2020 GS Capital Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. Additionally, GS Capital has the option to convert all or any amount of the principal face amount of the January 22, 2020 GS Capital Note at any time from the date of issuance and ending on the later of the maturity date and the date the Default Amount, which is an amount between 112% and 130% of an amount equal to the then outstanding principal amount of the January 22, 2020 GS Capital Note plus any interest accrued, is paid if an event of default occurs, for shares of the Company’s common stock at the then-applicable conversion price. The conversion price for the January 22, 2020 GS Capital Note shall be equal to a 40% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, GS Capital shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by GS Capital and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock which may be increased up to 9.99% upon 60 days prior written notice by the GS Capital to the Company. The note is treated as stock settled debt under ASC 480 and accordingly the Company recorded a $38,667 put premium. The January 22, 2020 GS Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% per annum, or if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. Further, certain events of default may trigger penalty and liquidated damage provisions.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting and Reporting Policies (Policies)	6 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated in Melbourne, Victoria Australia on October 15, 2007 as Propanc PTY LTD, and continues to be based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. On November 23, 2010, the Company was incorporated in the state of Delaware as Propanc Health Group Corporation. In January 2011, to reorganize the Company, we acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of December 31, 2019, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to better reflect the Company’s stage of operations and development. The Company has filed multiple patent applications relating to its lead product, PRP. The first application was filed in October 2010 in each of the countries listed in the table below. This application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Hong Kong, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, Republic of Korea and India. In Brazil and Canada, the patent application remains under examination. In 2016 and 2017 we filed other patent applications, as indicated below. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, which allows the applicants to seek protection for an invention in over 150 countries. Once national or regional applications are filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national or regional phase. One PCT application, filed in November 2016, entered the national phase in July 2018 in each of the countries listed in the table below. A second application filed in January 2017 entered the national phase commencing July 2018. A third application entered the national phase in October 2018. No. Title Country Case Status Date Filed 1. A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic reduction agent. USA, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Hong Kong, Japan, Indonesia, Israel, New Zealand, Malaysia, Singapore, Malaysia South Africa, Mexico, Republic of Korea and India Granted Oct-22-2010 Brazil and Canada Under Examination Divisional applications filed and under examination in Mexico and China USA Divisional application granted 2. Proenzyme composition Australia, Canada, China, Europe, Hong Kong, India, Indonesia, Israel, Japan, Malaysia, New Zealand, Singapore, South Africa and USA Application filed and pending Nov-11-2016 3. Cancer Treatment Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Malaysia, New Zealand, Singapore and USA Application filed and pending Jan-27-2017 4. Composition of proenzymes for cancer treatment Australia, China, Europe, Japan and USA Application filed and pending Apr-12-2017 The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development.
Decrease in Authorized Common Stock and Reverse Split	Decrease in Authorized Common Stock and Reverse Split On June 24, 2019, the Company effected a one-for-five hundred (1:500) reverse stock split whereby the Company (i) decreased the number of authorized shares of common stock, $0.001 par value per share, to 100,000,000 and (ii) decreased by a ratio of one-for-five hundred (1:500) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the consolidated financial statements to reflect the reverse stock split. On February 4, 2020 the Directors resolved to increase the Common Stock of the Company from 100,000,000 authorized shares to 1,000,000,000 authorized shares and believes that such number of authorized shares of Common Stock will be in the best interests of the Corporation and its stockholders because the Board believes that the availability of more shares of Common Stock for issuance will allow the Corporation greater flexibility in pursuing financing from investors, meeting business needs as they arise, taking advantage of favorable opportunities and responding to a changing corporate environment. The Company filed the necessary documents with the U.S. Securities and Exchange Commission on February 6, 2020 and at the date of this filing the increase in authorized shares to 1,000,000,000 has not yet been effected.
Basis of Presentation	Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three and six months ended December 31, 2019 and 2018 and cash flows for the six months ended December 31, 2019 and 2018 and our financial position at December 31, 2019 have been made. The Company’s results of operations for the three and six months ended December 31, 2019 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2020. Reference is frequently made herein to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”). This is the source of authoritative US GAAP recognized by the FASB to be applied to non-governmental entities. Each ASC reference in this Quarterly Report is presented with a three-digit number, which represents its Topic. As necessary for explanation and as applicable, an ASC topic may be followed with a two-digit subtopic, a two-digit section or a two-or-three-digit paragraph. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2019. The June 30, 2019 balance sheet is derived from those statements.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive subsidiary at December 31, 2019.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying unaudited condensed consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.
Foreign Currency Translation and Other Comprehensive Income (Loss)	Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar ($) and/or (USD) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. For the six months ended December 31, 2019, the Company recognized an exchange loss of approximately $575,700 on intercompany loans made by the parent to the subsidiary which have not been repaid as at December 31, 2019. As of December 31, 2019 and June 30, 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: December 31, 2019 June 30, 2019 Exchange rate on balance sheet dates USD : AUD exchange rate 0.7030 0.7153 Average exchange rate for the period USD : AUD exchange rate 0.6847 0.7009 The exchange rates used to translate amounts in AUD into USD for the period ended December 31, 2018 are: 0.7046 as of the balance sheet date and 0.7248 average exchange rate for that period. Change in Accumulated Other Comprehensive Income (Loss) by component during the six months ended December 31, 2019 was as follows: Foreign Beginning balance, June 30, 2019 $ 1,066,998 Foreign currency translation loss (65,807 ) Ending balance, December 31, 2019 $ 1,001,191
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 10 - Derivative Financial Instruments and Fair Value Measurements.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no cash equivalents as of December 31, 2019 or June 30, 2019.
Patents	Patents Patents are stated at cost and classified as intangible assets and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any product costs as long as we are in the startup stage. Accordingly, as the Company’s products were and are not currently approved for market, all historical patent costs incurred through December 31, 2019 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360-10, “ Long-lived assets,”
Australian Goods and Services Tax ("GST")	Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of December 31, 2019 and June 30, 2019, the Company was owed $2,432 and $5,439, respectively, from the Australian Taxation Office. These amounts were fully collected subsequent to the balance sheet reporting dates.
Derivative Instruments	Derivative Instruments ASC Topic 815, Derivatives and Hedging
Convertible Notes with Variable Conversion Options	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “ Distinguishing Liabilities from Equity
Income Taxes	Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act (“TCJA”) was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017. On December 22, 2017, the SEC Staff Accounting Bulletin No. 118 (“SAB 118”) was issued, which allows a company to recognize provisional tax amounts when it does not have the necessary information available, prepared or analyzed, including computations, in reasonable detail to complete its accounting for the change in tax law. SAB 118 provides for a measurement of up to one year from the date of enactment.
Research and Development Costs and Tax Credits	Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as an income tax benefit, in operations, upon receipt. During each of the six months ended December 31, 2019 and 2018, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $108,751 and $116,970, respectively, which is reflected as a tax benefit in the accompanying condensed consolidated statements of operations and comprehensive income (loss).
Stock Based Compensation	Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. There was no cumulative effect of adoption on July 1, 2019.
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. As of December 31, 2019, there were 1,975,059 warrants outstanding, 59,644 stock options and 15 convertible notes payable, which notes are convertible into approximately 10,200,000 shares of the Company’s common stock (based on the closing price on the last trading day of the quarter ended December 31, 2019). Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance. Such securities are considered dilutive securities which were excluded from the computation since the effect is anti-dilutive.
Leases	Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases On July 1, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Operating lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the condensed consolidated statements of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting and Reporting Policies (Tables)	6 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Translation Exchange Rates	As of December 31, 2019 and June 30, 2019, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: December 31, 2019 June 30, 2019 Exchange rate on balance sheet dates USD : AUD exchange rate 0.7030 0.7153 Average exchange rate for the period USD : AUD exchange rate 0.6847 0.7009
Schedule of Change in Accumulated Other Comprehensive Income (Loss)	Change in Accumulated Other Comprehensive Income (Loss) by component during the six months ended December 31, 2019 was as follows: Foreign Beginning balance, June 30, 2019 $ 1,066,998 Foreign currency translation loss (65,807 ) Ending balance, December 31, 2019 $ 1,001,191

Convertible Notes (Tables)

Convertible Notes (Tables)	6 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Convertible Notes	The Company’s convertible notes outstanding at December 31, 2019 were as follows: Convertible notes and debenture $ 2,016,365 Unamortized discounts (415,712 ) Accrued interest 182,581 Premiums 1,151,106 Convertible notes, net $ 2,934,340

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Right Use of Asset	ROU is summarized below: December 31, 2019 Office lease ROU $ 48,662 Less accumulated reduction (13,271 ) Balance of ROU asset as of December 31, 2019 $ 35,391
Schedule of Operating Lease Liability	Operating lease liability related to the ROU asset is summarized below: December 31, 2019 Office lease liability $ 48,662 Reduction of lease liability (11,352 ) Total 37,310 Less: current portion (14,216 ) Long term portion of lease liability as of December 31, 2019 $ 23,094
Schedule of Future Minimum Rental Payments for Operating Leases	Future Minimum lease payments under non-cancelable operating lease at December 31, 2019 are as follows: Remainder Fiscal Year 2020 $ 15,120 Year 2021 23,119 Total 38,239 Imputed interest (929 ) Total operating lease liability $ 37,310

Derivative Financial Instrume_2

Derivative Financial Instruments and Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	Convertible Debt Initial Valuations into during the six December 31, 2019 Volatility 227.82 % 227.82 % Expected Remaining Term (in years) 1 00.39 – 0.91 Risk Free Interest Rate 1.59 % 1.48% – 1.59 % Expected dividend yield None None
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2019: Balance at Quoted Prices in Active Markets for Identical Significant Other Observable Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 924,744 $ — $ — $ 924,744 Total $ 924,744 $ — $ — $ 924,744
Schedule of Derivative Liabilities at Fair Value	The following is a roll forward for the six months ended December 31, 2019 of the fair value liability of price adjustable derivative instruments: Fair Value of Liability for Derivative Instruments Balance at June 30, 2019 $ 698,264 Initial fair value of embedded conversion option derivative liability recorded as debt discount 115,000 Initial fair value of embedded conversion option derivative liability recorded as expense 93,125 Reductions due to conversions (44,588 ) Change in fair value included in statements of operations 62,943 Balance at December 31, 2019 $ 924,744

Nature of Operations and Summ_4

Nature of Operations and Summary of Significant Accounting and Reporting Policies (Details Narrative)	Jun. 24, 2019$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)	Feb. 06, 2020shares	Feb. 04, 2020shares	Jun. 30, 2019USD ($)$ / sharesshares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock	one-for-five hundred (1:500)
Common stock, par value | $ / shares	$ 0.001	$ 0.001		$ 0.001				$ 0.001
Common stock, shares authorized | shares	100,000,000	100,000,000		100,000,000				100,000,000
Recognized an exchange loss on foreign currency translation | $		$ (629,494)	$ 358,279	$ (65,807)	$ 634,495
Exchange rates to translate amounts		0.7030		0.7030				0.7153
Cash equivalents | $
Value added tax receivable | $		2,432		$ 2,432				$ 5,439
Income tax percentage description				On December 22, 2017, the passage of legislation commonly referred to as the Tax Cuts and Jobs Act ("TCJA") was enacted and significantly revised the U.S. income tax law. The TCJA includes changes, which reduce the corporate income tax rate from 34% to 21% for fiscal years beginning after December 31, 2017.
Research and development costs | $		37	94,777	$ 65,409	150,970
Tax credits | $		$ (143)	$ 116,970	$ 108,751	$ 116,970
Debt conversion percentage				4.99%
Debt conversion percentage, description				Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders' ability to increase such limitation to 9.99% upon 60 days' notice to the Company)
Share-based Payment Arrangement, Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount | shares				59,644
Convertible Notes Payable [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount | shares				15
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount | shares				1,975,059
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount | shares				10,200,000
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax percentage				34.00%
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax percentage				21.00%
AUD into USD Currency [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exchange rates to translate amounts			0.7046		0.7046
Average exchange rate			0.7248		0.7248
Intercompany Loans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Recognized an exchange loss on foreign currency translation | $				$ 575,700
Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized | shares						1,000,000,000	1,000,000,000

Nature of Operations and Summ_5

Nature of Operations and Summary of Significant Accounting and Reporting Policies - Schedule of Translation Exchange Rates (Details)	Dec. 31, 2019	Jun. 30, 2019
USD : AUD exchange rate	0.7030	0.7153
Weighted Average [Member]
USD : AUD exchange rate	0.6847	0.7009

Nature of Operations and Summ_6

Nature of Operations and Summary of Significant Accounting and Reporting Policies - Schedule of Change in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Beginning balance			$ 1,066,998
Foreign currency translation loss	$ (629,494)	$ 358,279	(65,807)	$ 634,495
Ending balance	$ 1,001,191		$ 1,001,191

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenues
Net loss	(1,867,109)	$ (1,491,940)	(1,450,038)	$ (2,124,936)	(3,359,049)	(3,574,974)
Net cash used in operating activities					(1,142,877)	(1,056,786)
Working capital deficit	(5,693,527)				(5,693,527)
Stockholders' deficit	(5,671,985)	$ (4,541,732)	$ (3,904,036)	$ (5,558,044)	(5,671,985)	$ (3,904,036)	$ (4,301,236)	$ (6,751,920)
Accumulated deficit	$ (54,400,096)				$ (54,400,096)		$ (51,041,047)

Due to Former Director - Rela_2

Due to Former Director - Related Party (Details Narrative) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Related Party Transactions [Abstract]
Due to directors - related parties	$ 31,257	$ 31,164

Loans and Notes Payable (Detail

Loans and Notes Payable (Details Narrative) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Directors and Officer [Member]
Loans payable	$ 52,022	$ 51,867

Convertible Notes (Details Narr

Convertible Notes (Details Narrative)	Dec. 03, 2019USD ($)	Nov. 26, 2019USD ($)$ / shares	Oct. 03, 2019USD ($)	Oct. 02, 2019USD ($)	Sep. 04, 2019USD ($)	Aug. 30, 2019USD ($)$ / sharesshares	Aug. 01, 2019USD ($)	Jul. 30, 2019USD ($)	Jul. 08, 2019USD ($)	Jul. 03, 2019USD ($)$ / shares	May 23, 2019USD ($)$ / shares	Dec. 24, 2018USD ($)Integer	Nov. 30, 2018USD ($)Integer	Oct. 02, 2018USD ($)Integer	Aug. 29, 2018USD ($)Integer	Jul. 19, 2018USD ($)	Jul. 13, 2018USD ($)Integer	Dec. 29, 2017USD ($)Integer	Aug. 10, 2017USD ($)Integer	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jan. 02, 2020USD ($)$ / shares	Sep. 10, 2019$ / sharesshares	Aug. 31, 2019$ / sharesshares	Jun. 30, 2019USD ($)	Oct. 03, 2018USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)
Convertible debt principal amount																						$ 267,187
Original issue discount																				$ 415,712
Proceeds from convertible debt																				$ 1,130,000	$ 1,054,089
Common stock trading volume, percent																				4.99%
Debt premium amount																				$ 1,151,106
Additional paid in capital																				47,766,162		$ 410,750			$ 45,713,322
Debt conversion of converted amount																				318,768
Embedded derivative, fair value of embedded derivative liability																				924,744
Conversion price, per share | $ / shares																						$ 0.165
Amortization of debt discount																				307,085	$ 303,813
Warrants to purchase of common stock, shares | shares																							1,000,000
Warrants exercise price per share | $ / shares																							$ 2
First Warrant [Member]
Warrants to purchase of common stock, shares | shares																								450,000
Warrants exercise price per share | $ / shares																								$ 2.25
Second Warrant [Member]
Warrants to purchase of common stock, shares | shares																								300,000
Warrants exercise price per share | $ / shares																								$ 3.33
Third Warrant [Member]
Warrants to purchase of common stock, shares | shares																								225,000
Warrants exercise price per share | $ / shares																								$ 4.50
Maximum [Member]
Conversion price, per share | $ / shares																						0.75
Minimum [Member]
Conversion price, per share | $ / shares																						$ 0.0672
December 29, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Convertible debt principal amount																				13,865
Accrued interest																				9,630
December 29, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2017 Eagle Note [Member]
Convertible debt principal amount																		$ 532,435		158,100					360,470
Original issue discount																		$ 25,354
Debt instrument, interest rate, stated percentage																		8.00%
Accrued interest																				22,478
Debt premium amount																		$ 354,956
Additional paid in capital																									240,313
December 29, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2017 Eagle Note One [Member]
Convertible debt principal amount																				158,100
Additional paid in capital																				105,400
December 29, 2017 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2017 Eagle Note [Member]
Proceeds from convertible debt																		$ 507,081
Debt maturity date																		Dec. 29, 2018
Common stock trading volume, percent																		60.00%
Common stock trading days | Integer																		10
Debt instrument, default, interest rate																		24.00%
July 13, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | July 2018 Eagle Note [Member]
Convertible debt principal amount																	$ 75,000			75,000
Proceeds from convertible debt																$ 71,250
Debt maturity date																	Jul. 13, 2019
Debt instrument, interest rate, stated percentage																	8.00%
Accrued interest																				$ 14,860
Common stock trading volume, percent																	60.00%
Common stock trading days | Integer																	10
Debt premium amount																	$ 50,000
Debt instrument, default, interest rate																				24.00%
Legal fees																$ 3,750
Percentage of outstanding shares of common stock																	4.99%
August 29, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | August 2018 Eagle Note [Member]
Convertible debt principal amount															$ 105,000					$ 105,000
Debt maturity date															Aug. 31, 2019
Debt instrument, interest rate, stated percentage															8.00%
Accrued interest																				$ 19,746
Common stock trading volume, percent															60.00%
Common stock trading days | Integer															10
Debt premium amount															$ 70,000
Debt instrument, default, interest rate																				24.00%
Percentage of outstanding shares of common stock															4.99%
Debt original issue discount, rate															10.00%
August 29, 2018 Securities Purchase Agreement [Member] | Depository Trust Company [Member] | August 29, 2018 Eagle Note [Member]
Common stock trading volume, percent															50.00%
October 2, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | October 2018 Eagle Note [Member]
Convertible debt principal amount														$ 210,000						$ 210,000
Debt maturity date														Oct. 2, 2019
Debt instrument, interest rate, stated percentage														8.00%
Accrued interest																				$ 29,227
Common stock trading volume, percent														60.00%
Common stock trading days | Integer														10
Debt premium amount														$ 140,000
Debt instrument, default, interest rate																				24.00%
Percentage of outstanding shares of common stock														4.99%
Debt instrument principal payment														$ 10,000
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Note [Member]
Convertible debt principal amount														212,000						$ 35,820						$ 106,000
Proceeds from convertible debt														$ 100,700
Debt maturity date														Oct. 2, 2019
Debt instrument, interest rate, stated percentage														8.00%
Accrued interest																				2,434
Common stock trading volume, percent														61.00%
Common stock trading days | Integer														10
Debt premium amount														$ 67,771						$ 22,901					44,690
Debt instrument, default, interest rate																				24.00%
Percentage of outstanding shares of common stock														4.99%
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Note [Member] | First Note [Member]
Proceeds from convertible debt														$ 106,000
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Note [Member] | Second Note [Member]
Proceeds from convertible debt														$ 106,000
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Back-End Note [Member]
Convertible debt principal amount																				$ 49,900
Debt maturity date																				Oct. 31, 2019
Debt premium amount																				$ 31,903
November 30, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | November 2018 Eagle Note [Member]
Convertible debt principal amount													$ 105,000							105,000
Debt maturity date													Nov. 30, 2019
Debt instrument, interest rate, stated percentage													8.00%
Accrued interest																				$ 10,540
Common stock trading volume, percent													61.00%
Common stock trading days | Integer													10
Debt premium amount													$ 67,131
Debt instrument, default, interest rate																				24.00%
Percentage of outstanding shares of common stock													4.99%
Debt original issue discount, rate													10.00%
Debt instrument principal payment													$ 5,000
November 30, 2018 Securities Purchase Agreement [Member] | Depository Trust Company [Member] | November 2018 Eagle Note [Member]
Common stock trading volume, percent													51.00%
December 24, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2018 Eagle Note [Member]
Convertible debt principal amount												$ 126,000								$ 126,000
Debt maturity date												Dec. 24, 2019
Debt instrument, interest rate, stated percentage												8.00%
Accrued interest																				$ 10,688
Common stock trading volume, percent												61.00%
Common stock trading days | Integer												10
Debt premium amount												$ 80,557
Debt instrument, default, interest rate																				24.00%
Percentage of outstanding shares of common stock												4.99%
Debt original issue discount, rate												10.00%
Debt instrument principal payment												$ 6,000
December 24, 2018 Securities Purchase Agreement [Member] | Depository Trust Company [Member] | December 2018 Eagle Note [Member]
Common stock trading volume, percent												51.00%
December 29, 2017, June 14, 2018, July 13, 2018, August 29, 2018, October 2, 2018, November 30, 2018 and December 24, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member]
Convertible debt principal amount																				$ 634,865
Accrued interest																				94,691
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]
Convertible debt principal amount																									35,820
Accrued interest																									7,813
October 2, 2018 Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Back-End Note [Member]
Convertible debt principal amount																									106,000
Accrued interest																									5,715
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | October 2018 GS Back End Note [Member]
Convertible debt principal amount																				56,100
Accrued interest																				11,814
Securities Purchase Agreement [Member] | Power Up Lending Group Ltd [Member] | July 3, 2019 Power Up Note [Member]
Convertible debt principal amount									$ 78,000	$ 78,000										78,000
Proceeds from convertible debt									75,000
Debt maturity date										Jul. 3, 2020
Debt instrument, interest rate, stated percentage										8.00%
Accrued interest																				3,086
Common stock trading volume, percent										65.00%
Debt instrument, default, interest rate										22.00%
Legal fees									2,500
Percentage of outstanding shares of common stock										150.00%
Embedded derivative, fair value of embedded derivative liability										$ 155,904
Conversion price, per share | $ / shares										$ 3.25
Debt instrument market price per share | $ / shares										$ 5
Debt instrument, description										The conversion price for the July 3, 2019 Power Up Note shall be $3.25, subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $5.00, the conversion price shall be the greater of 65% of the Market Price ("Variable Conversion Price") and $3.25. In the event Market Price is less than $5.00, the conversion price shall be the Variable Conversion Price. As defined in the July 3, 2019 Power Up Note, the "Market Price" shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the "pink sheets" during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock.
Diligence fees									$ 500
Securities Purchase Agreement [Member] | Power Up Lending Group Ltd [Member] | November 26, 2019 Power Up Note [Member]
Convertible debt principal amount	$ 40,000	$ 43,000																		43,000
Debt maturity date		Nov. 26, 2020
Debt instrument, interest rate, stated percentage		8.00%
Accrued interest																				329
Common stock trading volume, percent		65.00%
Debt instrument, default, interest rate		22.00%
Legal fees	2,500
Percentage of outstanding shares of common stock		150.00%
Embedded derivative, fair value of embedded derivative liability		$ 52,222
Conversion price, per share | $ / shares		$ 3.25
Debt instrument market price per share | $ / shares		$ 5
Debt instrument, description		The conversion price for the November 26, 2019 Power Up Note shall be $3.05, subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $5.00, the conversion price shall be the greater of 65% of the Market Price ("Variable Conversion Price") and $3.05. In the event Market Price is less than $5.00, the conversion price shall be the Variable Conversion Price. As defined in the November 26, 2019 Power Up Note, the "Market Price" shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the "pink sheets" during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock.
Diligence fees	$ 500
Securities Purchase Agreement [Member] | Odyssey Capital Funding LLC [Member] | July 2019 Odyssey Note [Member]
Convertible debt principal amount							$ 295,000	$ 320,000												320,000
Original issue discount								$ 25,000
Proceeds from convertible debt							285,000
Debt maturity date								Jul. 30, 2020
Debt instrument, interest rate, stated percentage								10.00%
Accrued interest																				13,464
Common stock trading volume, percent								65.00%
Debt premium amount								$ 172,308
Debt instrument, default, interest rate								24.00%
Legal fees							$ 10,000
Percentage of outstanding shares of common stock								120.00%
Debt instrument, description								Common Stock beneficially owned by the Holder and its affiliates would exceed 4.99% of the outstanding shares of the Common Stock of the Company (which may be increased up to 9.9% upon 60 days' prior written notice by the Holder to the Company).
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member]
Convertible debt principal amount					$ 550,000	$ 550,000														550,000
Proceeds from convertible debt					505,000
Debt maturity date						Aug. 30, 2020
Debt instrument, interest rate, stated percentage						10.00%
Accrued interest																				$ 18,484
Debt premium amount						$ 366,667
Debt instrument, default, interest rate						24.00%
Legal fees					5,000
Percentage of outstanding shares of common stock						125.00%														4.99%
Debt instrument, description						Upon the holder's election to convert accrued interest, default interest or any penalty amounts as stipulated, the Company may elect to pay those amounts in cash. The note may also be prepaid by the Company at any time between the date of issuance and August 13, 2020 at 135% multiplied by the sum of (a) the then outstanding principal amount plus (b) accrued and unpaid interest plus (c) default interests, if any. The conversion price for the August 30, 2019 Auctus Note shall be the Variable Conversion Price, being 60% of the Market Price. Notwithstanding the foregoing, Auctus shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Auctus and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock.
Diligence fees					$ 40,000
Fair value of warrants																				$ 375,904
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | First Warrant [Member]
Warrants to purchase of common stock, shares | shares						450,000
Warrants exercise price per share | $ / shares						$ 2.25
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Second Warrant [Member]
Warrants to purchase of common stock, shares | shares						300,000
Warrants exercise price per share | $ / shares						$ 3.33
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Third Warrant [Member]
Warrants to purchase of common stock, shares | shares						225,000
Warrants exercise price per share | $ / shares						$ 4.50
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Maximum [Member]
Convertible debt principal amount						$ 15,000
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | October 1, 2019 GW Note [Member]
Convertible debt principal amount				$ 131,000																131,000
Proceeds from convertible debt				$ 125,000
Debt maturity date				Oct. 1, 2020
Debt instrument, interest rate, stated percentage				8.00%
Accrued interest																				2,606
Debt premium amount				$ 87,333
Debt instrument, default, interest rate				24.00%
Percentage of outstanding shares of common stock				4.99%
Debt instrument principal payment				$ 6,000
Debt instrument, description				The conversion price for the October 1, 2019 GW Holdings Note shall be equal to a 40% discount of the lowest closing bid price ("Lowest Trading Price") of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, GW Holdings shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by GW Holdings and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock which may be increased up to 9.99% upon 60 days prior written notice by the GW Holdings to the Company.
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | October 1, 2019 GW Note [Member] | Maximum [Member]
Debt instrument, default, interest rate				150.00%
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | October 1, 2019 GW Note [Member] | Minimum [Member]
Debt instrument, default, interest rate				110.00%
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Original issue discount																				534,000
Debt premium amount																				539,000
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member]
Convertible debt principal amount			$ 108,000																	108,000
Original issue discount			5,000																	591,000
Proceeds from convertible debt			$ 100,000
Debt maturity date			Oct. 3, 2020
Debt instrument, interest rate, stated percentage			10.00%
Accrued interest																				2,626
Debt premium amount			$ 72,000																	698,000
Debt instrument, default, interest rate			15.00%
Percentage of outstanding shares of common stock			4.99%
Debt instrument principal payment			$ 3,000
Debt instrument, description			The conversion price for the October 3, 2019 Crown Bridge Note shall be equal to a 40% discount of the lowest closing bid price ("Lowest Trading Price") of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, Crown Bridge shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Crown Bridge and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock which may be increased up to 9.99% upon 60 days prior written notice by the Crown Bridge to the Company.
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member] | Maximum [Member]
Debt instrument, default, interest rate			150.00%
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member] | Minimum [Member]
Debt instrument, default, interest rate			110.00%
August 10, 2017 Consulting Agreement [Member]
Convertible debt principal amount																			$ 310,000	9,000
Debt maturity date																			Aug. 10, 2019
Debt instrument, interest rate, stated percentage																			10.00%
Accrued interest																				26,653
Common stock trading volume, percent																			65.00%
Common stock trading days | Integer																			10
Debt instrument, default, interest rate																			18.00%
Debt conversion of converted amount																			$ 750
Accrued expenses																											$ 155,000	$ 155,000
Embedded derivative, fair value of embedded derivative liability																			$ 578,212
August 10, 2017 Consulting Agreement [Member] | Consultant [Member]
Convertible debt principal amount																									161,000		140,000
Accrued interest																									19,418		$ 10,764
Redstart Holdings Corp Financing Agreement [Member]
Convertible debt principal amount																				46,600
Amortization of debt discount																				18,266
Redstart Holdings Corp Financing Agreement [Member] | Redstart Holdings Note [Member] | November 19, 2019 [Member]
Common stock trading volume, percent											65.00%
Debt instrument, default, interest rate											22.00%
Embedded derivative, fair value of embedded derivative liability											$ 166,564
Conversion price, per share | $ / shares											$ 32.50
Debt instrument market price per share | $ / shares											$ 50
Debt instrument, description											The Company had the right to prepay the May 2019 Redstart Holdings Note until November 19, 2019. If the May 2019 Redstart Holdings Note was prepaid within 90 days of the issuance date, then the prepayment premium shall be 115% of the face amount plus any accrued interest; if the May 2019 Redstart Holdings Note was prepaid after 91 days from the issuance date, but prior to 121 days from the issuance date, then the prepayment premium shall be 120% of the face amount plus any accrued interest; and if the May 2019 Redstart Holdings Note was prepaid after 121 days from the issuance date, but prior to 150 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest; and if the May 2019 Redstart Holdings Note was prepaid after 151 days from the issuance date, but prior to 180 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest.
Redstart Holdings Corp Financing Agreement [Member] | Redstart Holdings Corp [Member]
Convertible debt principal amount											$ 133,000									86,400					133,000
Proceeds from convertible debt											$ 130,000
Debt maturity date											May 23, 2020
Debt instrument, interest rate, stated percentage											8.00%
Accrued interest																				$ 6,322					$ 1,137
Legal fees											$ 3,000
Percentage of outstanding shares of common stock											4.99%

Convertible Notes - Schedule of

Convertible Notes - Schedule of Convertible Notes (Details)	Dec. 31, 2019USD ($)
Debt Disclosure [Abstract]
Convertible notes and debenture	$ 2,016,365
Unamortized discounts	(415,712)
Accrued interest	182,581
Premiums	1,151,106
Convertible notes, net	$ 2,934,340

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Sep. 10, 2019	Jul. 19, 2019	Jun. 24, 2019	May 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jan. 02, 2020	Aug. 31, 2019	Jun. 30, 2019	Dec. 09, 2014
Reverse stock split			one-for-five hundred (1:500)
Common stock, par value			$ 0.001		$ 0.001				$ 0.001
Common stock, shares authorized			100,000,000		100,000,000				100,000,000
Preferred stock, shares authorized					1,500,005				1,500,005	500,000
Preferred stock, par value					$ 0.01				$ 0.01
Common stock issued during period		20,000			1,246,859
Conversion price							$ 0.165
Conversion price, decrease					$ 0.067
Conversion price, increase					$ 0.906
Conversion of principal and interest, aggregate amount					$ 318,768
Additional paid in capital					47,766,162		$ 410,750		$ 45,713,322
Embedded derivative liability					$ 924,744
Common stock reserved for future issuances					77,292,139
Share issued price per share		$ 1.99
Proceeds from issuance of common stock		$ 39,800				$ 405,773
Consulting expenses					39,800
Number of restricted shares issued				78,000
Share Based Compensation					$ 150,208
Warrants to purchase common stock	1,000,000
Warrant exercise price	$ 2
Warrant expiration date	Sep. 10, 2022
Fair value of warrants	$ 984,810
Share-based Payment Arrangement, Option [Member]
Granted exercise price					$ 76.37
Share Based Compensation				$ 41,437
Grant options to purchase					59,644
Exercise price				$ 4.65
Risk free rate				2.42%
Dividend yield				0.00%
Fair value term				10 years
Expected volatility				268.00%
Option granted value				$ 248,620
Common Stock [Member]
Amount recorded to equity					$ 343,179
Embedded conversion option derivatives					46,600
Fair market value of shares issued value					71,011
Loss on extinguishment					24,411
Gain on extinguishment					44,587
Additional paid in capital					160,205
First Warrant [Member]
Warrants to purchase common stock								450,000
Warrant exercise price								$ 2.25
Second Warrant [Member]
Warrants to purchase common stock								300,000
Warrant exercise price								$ 3.33
Third Warrant [Member]
Warrants to purchase common stock								225,000
Warrant exercise price								$ 4.50
Warrant [Member]
Share Based Compensation					$ 984,810
Warrants outstanding and exercisable					1,975,059
Warrants expiration term description					As of December 31, 2019, there were 1,975,059 warrants outstanding and exercisable with expiration dates commencing May 2020 and continuing through August 2024, with a weighted average exercise price per share of $2.69.
Restricted Stock Units (RSUs) [Member]
Number of restricted shares issued				117,000
Granted exercise price				$ 4.25
Share based compensation arrangement by share based payment award options grant date fair value				$ 497,240
Share Based Compensation					$ 108,771
Unrecognized restricted stock units expense					357,392
Restricted Stock [Member]
Unvested stock option recognized					$ 196,824
Chief Executive Officer [Member]
Common stock issued during period				58,500
Number of restricted shares issued				39,000
Option Description				The total 58,500 options have a term of 10 years from the date of grant and exercise price ranging from $4.25 to $4.675 per share. 1/3rd of these options shall vest every successive one-year anniversary, provided, that on each such vesting date, the Chief Executive Officer and Chief Scientific Officer are employed by the Company and subject to the other provisions of the employment agreement. The 58,500 stock options were valued using a Black-Scholes model with the following assumptions: stock price at valuation date of $4.25 based on quoted trading price on date of grant, exercise price of $4.65, dividend yield of zero, years to maturity of 10.00, a risk free rate of 2.42%, and expected volatility 268% for a total value of $248,620.
Chief Executive Officer [Member] | Share-based Payment Arrangement, Option [Member]
Grant options to purchase				39,000
Chief Scientific Officer [Member] | Share-based Payment Arrangement, Option [Member]
Grant options to purchase				19,500
Convertible Debt [Member]
Conversion price					$ 0.3575
Embedded derivative liability					$ 343,179
Fair market value of shares					$ 343,179
Series A Preferred Stock [Member]
Preferred stock, shares authorized					500,000				500,000
Preferred stock, par value					$ 0.01				$ 0.01
Preferred stock, shares issued					500,000				500,000
Preferred stock, shares outstanding					500,000				500,000

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)	Sep. 26, 2019USD ($)	Sep. 13, 2018USD ($)	Sep. 13, 2018EUR (€)	Aug. 12, 2016USD ($)	May 05, 2016USD ($)	May 05, 2016AUD ($)	Jun. 30, 2012	Dec. 31, 2019USD ($)shares	Jun. 30, 2018USD ($)	Dec. 31, 2014USD ($)
Penalty amount										$ 30,000
Royalties percentage		2.00%	2.00%
Royalty Agreement Terms [Member]
Operating leases income statement revenue percentage							2.00%
License Agreement Terms [Member]
Operating leases income statement revenue percentage							5.00%
New Five-Year Operating Lease Agreement [Member]
Operating lease term					5 years	5 years
Payments for rent					$ 2,469
New Five-Year Operating Lease Agreement [Member] | AUD Currency [Member]
Payments for rent						$ 3,606
Manufacturing Services Agreement [Member] | Minimum [Member]
Anticipated milestone payment				$ 2,500,000
Manufacturing Services Agreement [Member] | Maximum [Member]
Anticipated milestone payment				$ 5,000,000
Amatsigroup Agreement [Member]
Payments description				The Company anticipates that its payments to Amatsigroup under the MSA will range between $2.5 million and $5.0 million over three years, when the finished drug product is manufactured and released for clinical trials. The Company has spent a total of $1,689,146 of costs to date under this contract of which $1,689,146 was expensed in prior years. The MSA shall continue for a term of three years unless extended by mutual agreement in writing.
Contract cost								$ 1,689,146	$ 1,689,146
One-Year Collaboration Agreement [Member]
Payment for services		$ 59,508
One-Year Collaboration Agreement [Member] | Euros [Member]
Payment for services | €			€ 52,000
Two-Year Collaboration Agreement [Member]
Payment for services		$ 45,775
Two-Year Collaboration Agreement [Member] | Euros [Member]
Payment for services | €			€ 40,000
From 2012 through the 2014 [Member]
Penalty amount								10,000
Regal Consulting, LLC [Member]
Loss contingency amount								$ 400,000
Number of shares issued for services | shares								60,000
Foley Shechter [Member]
Legal fees	$ 151,032

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Right Use of Asset (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Office lease ROU	$ 48,662
Less accumulated reduction	(13,271)
Balance of ROU asset	$ 35,391

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Operating Lease Liability (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Office lease liability	$ 48,662
Reduction of lease liability	(11,352)
Total	37,310
Less: current portion	(14,216)
Long term portion of lease liability	$ 23,094

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details)	Dec. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remainder Fiscal Year 2020	$ 15,120
Year 2021	23,119
Total	38,239
Imputed interest	(929)
Total operating lease liability	$ 37,310

Related Party Transactions (Det

Related Party Transactions (Details Narrative)

May 14, 2019USD ($)$ / sharesshares

May 14, 2019AUD ($)shares

Mar. 16, 2018USD ($)

Mar. 16, 2018AUD ($)

Feb. 01, 2018USD ($)

May 05, 2016USD ($)

May 05, 2016AUD ($)

Feb. 25, 2016USD ($)

Feb. 25, 2016AUD ($)

Feb. 25, 2015AUD ($)

May 31, 2019shares

Dec. 31, 2019USD ($)$ / shares

Dec. 31, 2019AUD ($)

Mar. 31, 2019USD ($)

Mar. 31, 2019AUD ($)

Jun. 30, 2019USD ($)

Jun. 30, 2019AUD ($)

Jun. 30, 2018USD ($)

Jun. 30, 2018AUD ($)

Dec. 31, 2019AUD ($)

May 05, 2016AUD ($)

Loans from related party

$ 52,022

$ 51,867

Due to related parties

$ 31,257

31,164

Restricted stock shares of common stock | shares

78,000

Stock price | $ / shares

$ 0.38

Board of Directors [Member]

Payments form related party

$ 56,056

Chief Executive Officer [Member]

Payments form related party

$ 94,228

64,377

Bonus payable amount

137,120

Remaining bonus amount

178,256

Remaining due and payable

163,363

Restricted stock shares of common stock | shares

39,000

Nathanielsz Employment Agreement [Member]

Expired date

Feb. 25, 2019

Annual salary

$ 205,680

Percentage of pension of monthly salary

9.50%

9.50%

Percentage of bonus of annual base salary

200.00%

200.00%

Nathanielsz Employment Agreement [Member] | Minimum [Member]

Annual salary

$ 205,680

Nathanielsz Employment Agreement [Member] | Maximum [Member]

Annual salary

274,240

AUD Currency [Member] | Board of Directors [Member]

Payments form related party

$ 80,046

AUD Currency [Member] | Chief Executive Officer [Member]

Payments form related party

$ 137,620

$ 90,000

Bonus payable amount

200,000

Remaining bonus amount

$ 260,000

Remaining due and payable

232,380

AUD Currency [Member] | Nathanielsz Employment Agreement [Member]

Annual salary

$ 25,000

300,000

AUD Currency [Member] | Nathanielsz Employment Agreement [Member] | Minimum [Member]

Annual salary

$ 300,000

AUD Currency [Member] | Nathanielsz Employment Agreement [Member] | Maximum [Member]

Annual salary

400,000

Initial Nathanielsz RSUs [Member] | Employment Agreement [Member]

Restricted stock shares of common stock | shares

39,000

39,000

Additional Nathanielsz RSUs [Member] | Employment Agreement [Member]

Restricted stock shares of common stock | shares

39,000

39,000

RSUS vest, shares | shares

7,800

7,800

Gross proceeds from equity financing

$ 4,000,000

Restricted Stock Units [Member] | Employment Agreement [Member]

Restricted stock shares of common stock | shares

78,000

78,000

Stock price | $ / shares

$ 4.25

Restricted stock value

$ 331,500

Fair value of restricted stock

$ 165,747

Initial Kenyon RSUs [Member] | Services Agreement [Member]

Restricted stock shares of common stock | shares

19,500

19,500

Additional Kenyon RSUs [Member] | Services Agreement [Member]

Restricted stock shares of common stock | shares

19,500

19,500

RSUS vest, shares | shares

4,875

4,875

Gross proceeds from equity financing

$ 4,000,000

North Horizon Pty Ltd [Member]

Lease term

5 years

5 years

Annual rental payments

$ 28,790

Goods and service tax

2,618

Future minimum payments due

$ 41,044

North Horizon Pty Ltd [Member] | AUD Currency [Member]

Annual rental payments

$ 42,048

Goods and service tax

$ 3,823

North Horizon Pty Ltd [Member] | AUD Currency [Member]

Future minimum payments due

$ 59,943

Current and Former Director [Member]

Loans from related party

52,022

51,867

Former Director [Member]

Due to related parties

31,257

$ 31,164

Nathanielsz [Member] | North Horizon Pty Ltd [Member]

Future minimum payments due

$ 143,953

Nathanielsz [Member] | North Horizon Pty Ltd [Member] | AUD Currency [Member]

Future minimum payments due

$ 210,242

Mr. Nathanielsz [Member]

Annual salary

$ 82,272

Payments form related party

$ 14,638

Mr. Nathanielsz [Member] | Board of Directors [Member]

Payments form related party

$ 154,100

Mr. Nathanielsz [Member] | AUD Currency [Member]

Payments form related party

$ 21,378

Mr. Nathanielsz [Member] | AUD Currency [Member] | Board of Directors [Member]

Payments form related party

$ 219,954

James Nathanielsz [Member]

Payments form related party

$ 3,205

James Nathanielsz [Member] | AUD Currency [Member]

Payments form related party

$ 4,481

Mr. Nathanielsz [Member] | Board of Directors [Member]

Officers' compensation

$ 315,376

$ 210,090

Mr. Nathanielsz [Member] | Employment Agreement [Member]

Agreement term

3 years

3 years

Agreement renewal term

1 year

1 year

Option purchase shares | shares

39,000

39,000

Excercise price | $ / shares

$ 4.675

Market price

110.00%

110.00%

Granted exercise price | $ / shares

$ 4.25

Restricted stock shares of common stock | shares

39,000

39,000

Option term

10 years

10 years

Options vested, description

The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz's continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz's continued employment with the Company through the applicable vesting date: (i) 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the "CTA") for PRP, the Company's lead product candidate ("PRP"), for a First-In-Human study for PRP (the "Study") in an applicable jurisdiction to be selected by the Company, (ii) 7,800 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7,800 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7,800 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested restricted stock unit shall be settled by delivery to Mr. Nathanielsz of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the 2019 Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Employment Agreement), (ii) the date that is ten business days following the vesting of such restricted stock unit, (iii) the date of Mr. Nathanielsz's death or Disability (as defined in the Employment Agreement), and (iv) Mr. Nathanielsz's employment being terminated either by the Company without Cause or by Mr. Nathanielsz for Good Reason (each as defined in the Employment Agreement). In the event of a Change of Control, any unvested portion of the Nathanielsz Options and such restricted stock units shall vest immediately prior to such event.

The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz's continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz's continued employment with the Company through the applicable vesting date: (i) 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the "CTA") for PRP, the Company's lead product candidate ("PRP"), for a First-In-Human study for PRP (the "Study") in an applicable jurisdiction to be selected by the Company, (ii) 7,800 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7,800 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7,800 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7,800 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested restricted stock unit shall be settled by delivery to Mr. Nathanielsz of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the 2019 Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Employment Agreement), (ii) the date that is ten business days following the vesting of such restricted stock unit, (iii) the date of Mr. Nathanielsz's death or Disability (as defined in the Employment Agreement), and (iv) Mr. Nathanielsz's employment being terminated either by the Company without Cause or by Mr. Nathanielsz for Good Reason (each as defined in the Employment Agreement). In the event of a Change of Control, any unvested portion of the Nathanielsz Options and such restricted stock units shall vest immediately prior to such event.

Stock price | $ / shares

$ 4.25

Restricted stock value

$ 165,747

Exercise price | $ / shares

$ 4.65

Dividend yield

0.00%

0.00%

Years to maturity

10 years

10 years

Risk free rate

2.42%

2.42%

Expected volatility

268.00%

268.00%

Mr. Nathanielsz [Member] | AUD Currency [Member] | Board of Directors [Member]

Officers' compensation

$ 460,000

$ 300,000

Mr. Nathanielsz [Member] | AUD Currency [Member] | Employment Agreement [Member]

Annual salary

400,000

Dr Kenyon [Member] | AUD Currency [Member] | Services Agreement [Member]

Annual salary

$ 54,000

Dr Kenyon [Member] | Services Agreement [Member]

Agreement term

3 years

3 years

Agreement renewal term

1 year

1 year

Option purchase shares | shares

19,500

19,500

Excercise price | $ / shares

$ 4.25

Market price

100.00%

100.00%

Granted exercise price | $ / shares

$ 19,500

Option term

10 years

10 years

Options vested, description

The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon's continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon's continued employment with the Company through the applicable vesting date: (i) 4,875 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 4,875 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii) 4,875 of the Additional Kenyon RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (iv) the remaining 4,875 of the Additional Kenyon RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested Kenyon RSU shall be settled by delivery to Mr. Kenyon of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Services Agreement), (ii) the date that is ten business days following the vesting of such Kenyon RSU, (iii) the date of Dr. Kenyon's death or Disability (as defined in the Services Agreement), and (iv) Dr. Kenyon's employment being terminated either by the Company without Cause or by Dr. Kenyon for Good Reason (as defined in the Services Agreement). In the event of a Change of Control (as defined in the Services Agreement), 50% of any unvested portion of the Kenyon Options and the Kenyon RSUs shall vest immediately prior to such event.

The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon's continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon's continued employment with the Company through the applicable vesting date: (i) 4,875 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 4,875 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii) 4,875 of the Additional Kenyon RSUs shall vest upon the shares of the Company's Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (iv) the remaining 4,875 of the Additional Kenyon RSUs shall vest upon the Company enrolling its first patient in the Study. Each vested Kenyon RSU shall be settled by delivery to Mr. Kenyon of one share of the Company's common stock and/or the fair market value of one share of common stock in cash, at the sole discretion of the Company's board of directors and subject to the Plan, on the first to occur of: (i) the date of a Change of Control (as defined in the Services Agreement), (ii) the date that is ten business days following the vesting of such Kenyon RSU, (iii) the date of Dr. Kenyon's death or Disability (as defined in the Services Agreement), and (iv) Dr. Kenyon's employment being terminated either by the Company without Cause or by Dr. Kenyon for Good Reason (as defined in the Services Agreement). In the event of a Change of Control (as defined in the Services Agreement), 50% of any unvested portion of the Kenyon Options and the Kenyon RSUs shall vest immediately prior to such event.

Stock price | $ / shares

$ 4.25

Restricted stock value

$ 82,873

Exercise price | $ / shares

$ 4.25

Dividend yield

0.00%

0.00%

Years to maturity

10 years

10 years

Risk free rate

2.42%

2.42%

Expected volatility

268.00%

268.00%

Dr Kenyon [Member] | Restricted Stock [Member] | Services Agreement [Member]

Restricted stock shares of common stock | shares

39,000

39,000

Stock price | $ / shares

$ 4.25

Restricted stock value

$ 165,750

Fair value of restricted stock

$ 82,873

Concentrations and Risks (Detai

Concentrations and Risks (Details Narrtive)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2019
Risks and Uncertainties [Abstract]
Reimbursement on goods and service tax receivable percentage	100.00%	100.00%

Derivative Financial Instrume_3

Derivative Financial Instruments and Fair Value Measurements (Details Narrative)	Dec. 31, 2019USD ($)$ / shares
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Convertible debt | $	$ 216,400
Share price | $ / shares	$ 0.38

Derivative Financial Instrume_4

Derivative Financial Instruments and Fair Value Measurements - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (Details)	6 Months Ended
	Dec. 31, 2019
Volatility [Member]
Derivative liability , measurement input, percentages	227.82
Volatility [Member] | Convertible Debt [Member]
Debt instrument, measurement input, percentages	227.82
Expected Remaining Term [Member]
Derivative liability, measurement input, term	1 year
Expected Remaining Term [Member] | Convertible Debt [Member] | Minimum [Member]
Debt instrument, measurement input, term	4 months 20 days
Expected Remaining Term [Member] | Convertible Debt [Member] | Maximum [Member]
Debt instrument, measurement input, term	10 months 28 days
Risk Free Interest Rate [Member]
Derivative liability , measurement input, percentages	1.59
Risk Free Interest Rate [Member] | Convertible Debt [Member] | Minimum [Member]
Debt instrument, measurement input, percentages	1.48
Risk Free Interest Rate [Member] | Convertible Debt [Member] | Maximum [Member]
Debt instrument, measurement input, percentages	1.59
Expected Dividend Yield [Member]
Derivative liability , measurement input, percentages	0
Expected Dividend Yield [Member] | Convertible Debt [Member]
Debt instrument, measurement input, percentages	0

Derivative Financial Instrume_5

Derivative Financial Instruments and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)	Dec. 31, 2019	Jun. 30, 2019
Embedded conversion option liabilities	$ 924,744
Total	924,744	$ 698,264
Fair Value, Inputs, Level 1 [Member]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Embedded conversion option liabilities	924,744
Total	$ 924,744

Derivative Financial Instrume_6

Derivative Financial Instruments and Fair Value Measurements - Schedule of Derivative Liabilities at Fair Value (Details)	6 Months Ended
	Dec. 31, 2019USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Balance at Beginning	$ 698,264
Initial fair value of embedded conversion option derivative liability recorded as debt discount	115,000
Initial fair value of embedded conversion option derivative liability recorded as expense	93,125
Reductions due to conversions	(44,588)
Change in fair value included in statements of operations	62,943
Balance at Ending	$ 924,744

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Feb. 04, 2020	Jan. 28, 2020	Jan. 22, 2020	Jan. 15, 2020	Jan. 13, 2020	Jan. 07, 2020	Jan. 02, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Feb. 06, 2020	Jul. 19, 2019	Jun. 30, 2019	Jun. 24, 2019
Debt conversion shares							2,804,424
Debt conversion price per share							$ 0.165
Debt principal amount							$ 267,187
Bifurcated embedded conversion option derivatives							82,500
Fair value of derivative liability							228,863
Loss on extinguishment							146,367	$ 20,176		$ (20,355)	$ 20,176	$ 1,165,516
Additional paid in capital							$ 410,750	$ 47,766,162			$ 47,766,162				$ 45,713,322
Common stock, shares authorized								100,000,000			100,000,000				100,000,000	100,000,000
Debt premium amount								$ 1,151,106			$ 1,151,106
Debt conversion threshold percentage											4.99%
Sale of stock price per share														$ 1.99
Value of stock issued for the services									$ 39,800	$ 69,000
Original debt discount								$ 415,712			$ 415,712
Proceeds from convertible note											$ 1,130,000	$ 1,054,089
Subsequent Event [Member]
Common stock, shares authorized	1,000,000,000												1,000,000,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | January 13, 2020 Ader Alef Note [Member]
Debt principal amount					$ 110,250
Legal expenses					$ 5,000
Debt maturity date					Jan. 13, 2021
Debt interest rate					8.00%
Debt premium amount					$ 59,365
Debt conversion, description					The conversion price for the January 13, 2020 Ader Alef Note during the first 6 months the January 13, 2020 Ader Alef Note is in effect shall be fixed at $2.50 and thereafter shall be equal to a 35% discount of the lowest closing bid price ("Lowest Trading Price") of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, Ader Alef shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Ader Alef and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock which may be increased up to 9.99% upon 60 days prior written notice by the Ader Alef to the Company.
Debt conversion threshold percentage					35.00%
Outstanding common stock percentage					4.99%
Debt instrument effective interest rate					24.00%
Original debt discount					$ 5,250
Proceeds from convertible note				$ 100,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Power Up Lending Group Ltd [Member] | January 7, 2020 Power Up Note [Member]
Debt principal amount					72,000	$ 75,000
Bifurcated embedded conversion option derivatives						$ 307,400
Legal expenses					2,500
Diligence fees					$ 500
Debt maturity date						Jan. 7, 2021
Debt interest rate						8.00%
Debt default amount percentage						150.00%
Debt conversion, description						The conversion price for the January 7, 2020 Power Up Note shall be $3.05, subject to certain Market Price (as defined below) adjustment. If the Market Price is greater than or equal to $5.00, the conversion price shall be the greater of 65% of the Market Price ("Variable Conversion Price") and $3.05. In the event Market Price is less than $5.00, the conversion price shall be the Variable Conversion Price. As defined in the January 7, 2020 Power Up Note, the "Market Price" shall be the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the "pink sheets" during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock.
Debt conversion threshold percentage						65.00%
Outstanding common stock percentage						4.99%
Debt instrument effective interest rate						22.00%
Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | January 22, 2020 GS Note [Member]
Debt principal amount			$ 58,000
Legal expenses			$ 2,500
Debt maturity date			Jan. 22, 2021
Debt interest rate			10.00%
Debt premium amount			$ 38,667
Debt conversion, description			The conversion price for the January 22, 2020 GS Capital Note shall be equal to a 40% discount of the lowest closing bid price ("Lowest Trading Price") of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, GS Capital shall be restricted from effecting a conversion if such conversion, along with other shares of the Company's common stock beneficially owned by GS Capital and its affiliates, exceeds 4.99% of the outstanding shares of the Company's common stock which may be increased up to 9.99% upon 60 days prior written notice by the GS Capital to the Company.
Debt conversion threshold percentage			40.00%
Outstanding common stock percentage			4.99%
Debt instrument effective interest rate			24.00%
Original debt discount			$ 3,500
Proceeds from convertible note		$ 52,000
Subsequent Event [Member] | Consulting Services Agreement [Member] | January 7, 2020 Consulting Services Agreement [Member]
Stock issued for the services, shares	150,000
Sale of stock price per share	$ 0.14
Value of stock issued for the services	$ 21,000
Minimum [Member]
Debt conversion price per share							$ 0.0672
Minimum [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member] | January 13, 2020 Ader Alef Note [Member]
Debt default amount percentage					112.00%
Minimum [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | January 22, 2020 GS Note [Member]
Debt default amount percentage			112.00%
Maximum [Member]
Debt conversion price per share							$ 0.75
Maximum [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member] | January 13, 2020 Ader Alef Note [Member]
Debt default amount percentage					135.00%
Maximum [Member] | Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | January 22, 2020 GS Note [Member]
Debt default amount percentage			130.00%